<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Shareholder Vision &#187; Featured</title>
	<atom:link href="http://www.shareholdervision.com/category/featured/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.shareholdervision.com</link>
	<description>Putting the markets in motion</description>
	<lastBuildDate>Tue, 21 Jun 2011 08:44:51 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Vicor Technologies, Inc. Exclusive Update</title>
		<link>http://www.shareholdervision.com/2011/06/vicor/</link>
		<comments>http://www.shareholdervision.com/2011/06/vicor/#comments</comments>
		<pubDate>Tue, 21 Jun 2011 07:18:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[VCRT]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/?p=288</guid>
		<description><![CDATA[This is Shareholder Vision's Second Visit to Vicor Technologies.  We visit again with David Fater, President and CEO of Vicor Technologies.]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/288.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<p><span style="font-family: times new roman,times;"><span style="font-size: medium;"><strong>Vicor Technologies, Inc.<br />
Website: </strong><a href="http://vicortech.com">http://www.VicorTech.com</a><br />
2300 NW Corporate Blvd. Suite 123<br />
Boca Raton, FL  33431<br />
Phone: 877-528-PD2i (7324)</span></span></p>
<p><strong><br />
</strong></p>
<p><img src="http://www.sguru.co/lt/VCRT/logo450.png" alt="" /></p>
<p><span style="color: #800000;"><strong><span style="font-size: medium;">Vicor Technologies, Inc. (OTCBB: VCRT) </span></strong></span>is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i <sup>® </sup>Algorithm and software.</p>
<p>With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.</p>
<p>The Company has all of the regulatory approvals in place already with regards to PD2i <sup>® </sup>to generate substantial revenues.</p>
<p><span style="font-size: medium; color: #800000;"><strong>FDA Approval of PD2i Analyzer™ for BOTH Heart Rate Variability and Cardiovascular Disease Testing</strong></span></p>
<p>Vicor’s PD2i Analyzer™ has FDA 510(k) marketing clearance to both:</p>
<ul>
<li>Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.</li>
<li>And be used specifically in patients undergoing cardiovascular disease testing.</li>
</ul>
<p><span style="font-size: medium; color: #800000;"><strong>Potential Market PD2i Analyzer™</strong></span></p>
<p>The potential market for the PD2i Analyzer™ with 77 million potential patients could be in the multi-billions of dollars.  This market is supported by the recent FDA approval to market the PD2i Analyzer™  for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer™ as a valuable new diagnostic.</p>
<p>The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i<sup>® </sup><sup> </sup>metric includes the classical Ewing maneuvers with the PD2i<sup>® </sup>metric in patients undergoing cardiovascular disease testing.</p>
<p>This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i <sup>® </sup>technology by Vicor in 2003.</p>
<p><img src="http://www.sguru.co/lt/VCRT/ppt2.jpg" alt="" /></p>
<p>These populations are significant:</p>
<ul>
<li>23.6 million diabetics</li>
<li>15 million at-risk cardiac patients</li>
<li>38 million trauma incidents</li>
</ul>
<p><span style="font-size: medium; color: #800000;"><strong>PD2i <sup>® </sup>Analyzer </strong><strong>Provides Additional Revenue Source for Physicians and Improves Patient Care</strong></span></p>
<p>Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.</p>
<p>Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.  Physicians are able to use the Analyzer for indications believed to be useful.  FDA clearance of specific indications allows Vicor to explicitly market for those indications.</p>
<p>Current procedural terminology (CPT) codes enable physicians using the PD2i<sup>® </sup> Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.</p>
<p>The PD2i<sup>® </sup> Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.</p>
<p>The PD2i <sup>® </sup>Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.</p>
<p><img src="http://www.sguru.co/lt/VCRT/ppt1.jpg" alt="" /></p>
<p><span style="font-size: medium; color: #800000;"><strong>PD2i </strong><strong><sup>® </sup>Algorithm New and Accurate Vital Sign</strong></span></p>
<p>The Company believes that the PD2i <sup>® </sup>Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.</p>
<p><span style="background-color: #ffffff;">Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i <sup>® </sup>Algorithm: </span></p>
<ul>
<li>First &#8211; the PD2i<sup>® </sup> Analyzer</li>
<li>Second - the PD2i Cardiac Analyzer ™</li>
<li>The PD2i VS ™ Vital Sign Monitor for trauma, triage, and other hospital uses in still  under development.</li>
</ul>
<p>&nbsp;</p>
<p><span style="color: #800000; font-size: medium;"><strong>FDA Clearance</strong></span></p>
<p>In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i<sup>® </sup> nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.</p>
<p>Physician use of the PD2i<sup>® </sup> Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i<sup>® </sup> nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.</p>
<p><img src="http://www.sguru.co/lt/VCRT/11.jpg" alt="" width="189" height="126" /></p>
<p><span style="font-size: medium; color: #800000;"><strong>Physician Use Includes :</strong></span></p>
<ul>
<li>Diabetics for the presence of diabetic autonomic neuropathy (DAN),</li>
<li>Cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and</li>
<li>Trauma victims for imminent death absent immediate lifesaving intervention.</li>
</ul>
<p><span style="font-size: medium; color: #800000;"><strong>Sales</strong></span></p>
<p>The Company has engaged various independent sales agents and sales representatives to market and sell its products in selected geographic areas in the United States.</p>
<p>Revenues will be predominately the result of equipment sales, fees from physicians and other health-care providers related to the analysis of test results and licensing fees.</p>
<p><img src="http://www.sguru.co/lt/VCRT/analyzer.jpg" alt="" /><br />
<img src="http://sguru.co/l/vcrt/result-1.png" alt="" width="354" height="411" /></p>
<p>&nbsp;</p>
<p><img src="http://sguru.co/l/vcrt/result-2.png" alt="" width="366" height="400" /></p>
<p>&nbsp;</p>
<p><img src="http://sguru.co/l/vcrt/result-3.png" alt="" width="468" height="393" /></p>
<p style="padding-left: 30px;"><strong> </strong></p>
<p><span style="font-size: medium; color: #800000;"><strong>Revenue Sources</strong></span></p>
<p>A national sales manager with a long and successful history in   medical device sales has been retained.  The sales force has expanded   geographically.  Vicor expects to continue to increase the size of its   domestic sales force throughout 2011, to approximately 70 Sales   Representatives by the end of 2011</p>
<p style="padding-left: 30px;"><strong>Equipment sales:</strong> Sales to physicians and other health care providers through both sales   representatives employed by the Company and also independent sales   agents.</p>
<p style="padding-left: 30px;"><strong>Leasing option:</strong> Agreement with equipment leasing company signed in early 2011 allows physicians to obtain the Analyzer without the upfront cost.</p>
<p style="padding-left: 30px;"><strong>International Distribution:</strong> An agreement with a distributor for Asia and Israel has been reached.  Vicor  currently is negotiating contracts for distribution in Middle East and  Europe.</p>
<p style="padding-left: 30px;"><strong>Current procedural terminology: (CPT) codes </strong>enable physicians using  the PD2i<sup>® </sup> Analyzer to measure HRV to be reimbursed by insurance  carriers, creating a recurring source of revenue from test analysis for  Vicor.</p>
<p><span style="font-size: medium; color: #800000;"><strong>Direct Marketing to Cardiologists</strong></span></p>
<p>FDA approval enables Vicor to market the PD2i<sup>® </sup> Analyzer directly to cardiologists as a diagnostic specifically targeted for use in cardiovascular disease testing.</p>
<p>VCRT is focused on spurring market acceptance of the PD2i<sup>® </sup> Analyzer as a valuable new diagnostic for cardiovascular disease testing.</p>
<p>Including the Ewing Maneuvers which are performed during PD2i Analyzer™ ECG data collection.</p>
<p>This recognition represents the PD2i<sup>® </sup> Analyzer as a meaningful metric for cardiovascular testing and validation of, from a regulatory perspective, our use of the Internet for the delivery of test data and analyses.</p>
<p>While cardiologists are already among users of the PD2i<sup>® </sup> Analyzer as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health, the Company anticipates this new clearance will contribute positively to the cardiologist-directed marketing efforts of the PD2i<sup>® </sup> Analyzer.</p>
<p><span style="color: #800000; font-size: medium;"><strong>Plan of Operations </strong></span></p>
<p style="padding-left: 30px;">1.   Increasing sales of the PD2i<sup>® </sup> Analyzer to physicians and health care facilities in the United States through the use of independent sales agents and direct sales personnel.</p>
<p style="padding-left: 30px;">2.     Raising additional capital with which to expand the sales and administrative infrastructure and fund ongoing operations until our operations generate positive cash flow.</p>
<p style="padding-left: 30px;">3.      Completing various clinical trials and 510(k) submissions to secure additional marketing claims for the PD2i<sup>® </sup> Analyzer to enhance and accelerate marketing efforts.</p>
<p style="padding-left: 30px;">4.      Initiating international sales of the PD2i<sup>® </sup> Analyzer and PD2i-VS<sup>® </sup> (Vital Sign), including securing CE Mark Clearance.</p>
<p>Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or resulting from inaccurate identification are garnering increased attention in the current health care reform environment.</p>
<p><span style="font-size: medium; color: #800000;"><strong>Conference Exposure</strong></span></p>
<p>Exposure through presentations at prestigious events and publication  in prominent journals is one of the most influential forms of marketing  and Vicor has extensive participation conference plans for 2011.</p>
<p>This direct exposure to physicians and the medical community represents a potential catalyst for sales and growth.</p>
<p>&nbsp;</p>
<p><span style="font-size: medium; color: #800000;"><strong>The Company has attended recent conferences including:</strong></span></p>
<ul>
<li>The American Heart Association in November of 2010</li>
<li>The American College of Cardiology in April of 2011.  One of Vicor&#8217;s congestive heart failure studies was presented by the researcher.</li>
<li>Vicor was just in attendance at the Heart Rhythes Society Conference in May</li>
<li>Vicor&#8217;s Chief Medical Officer is due to make a presentation to the Israeli Trauma Society meeting this summer.</li>
</ul>
<p>&nbsp;</p>
<p><span style="color: #800000; font-size: medium;"><strong>Clinical Studies</strong></span></p>
<p>Clinical studies completed or initiated have been conclusive concerning the ability of the PD2i <sup>® </sup>metric to be predictive of future pathological events.</p>
<p>This is of great significance to the medical community in terms of enabling physicians to easily risk stratify their patients as well as use these results to better manage their care.</p>
<p>The body of literature documenting the PD2i(R) nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events is constantly expanding.</p>
<p>Over 60 published manuscripts exist regarding the use of the PD2i<sup>® </sup>by physicians and scientists around the world in a multitude of disease states and modalities exist . Many of the researchers are well published and respected internationally.</p>
<p>These independent studies, which are not for FDA-approved indications, include the use of Vicor&#8217;s PD2i<sup>® </sup> nonlinear algorithm to:</p>
<ul>
<li><span style="background-color: #ffffff;">Predict seizure</span></li>
<li><span style="background-color: #ffffff;">Monitor transplant rejection</span></li>
<li><span style="background-color: #ffffff;">Analyze ventricular fibrillation</span></li>
<li><span style="background-color: #ffffff;">Identify depression</span></li>
<li><span style="background-color: #ffffff;">Determine risk in Sleep apnea</span></li>
<li><span style="background-color: #ffffff;">Autoimmune system imbalance detection</span></li>
<li><span style="background-color: #ffffff;">See the increased neural complexity in schizophrenic patients</span></li>
<li><span style="background-color: #ffffff;">Determine the impact of ECT therapy on depression</span></li>
<li><span style="background-color: #ffffff;">Monitor the effect of estrogen and testosterone on  convergent and divergent thinking</span></li>
<li><span style="background-color: #ffffff;">Locate seizure focus for epileptic surgery.</span></li>
</ul>
<p>These independent studies attest that Vicor&#8217;s PD2i<sup>® </sup> nonlinear algorithm has successfully demonstrated the ability to accurately measure heart rate variability to predict and identify a variety of medical conditions and disorders.</p>
<p>The range of human conditions and disorders that can be identified early in their arc and thereby provide physicians with the ability to enhance patient treatment and outcomes.</p>
<p>Continuing clinical studies are ongoing in a variety of areas &#8212; chief among these, sudden cardiac death and head trauma in athletes &#8212; to establish the PD2i<sup>® </sup>Analyzer as a widely used diagnostic in the clinical setting.</p>
<p>&nbsp;</p>
<div id="wp-content">
<div id="post-100">
<div>
<p><span style="color: #800000; font-size: medium;"><strong>Patent and Proprietary Rights</strong></span></p>
<p>Vicor has issued patents covering the core systems with the PD2i® Algorithm and methods of identifying biological anomalies using this algorithm as well as issued patents covering machines and methods for data manipulation for use with the PD2i® Algorithm from United States of America (5,709,214), United States of America (5,720,294), Azerbaijan (008979), Armenia (008979), Belarus (008979), Kazakhstan (008979), Kyrgyzstan (008979), Moldova, Republic of (008979), New Zealand (54202), Russian Federation (008979), South Africa (2005/06909), Tajikistan (008979), Turkmenistan (008979), United States of America (7,076,288) and United States of America (7,276,026). It has been allowed in Australia (Australian Patent Application 2004208161) and Israel (Israel Patent Application 169988). There are also a number of patent applications around the world covering additional aspects and uses of the PD2i® technology, which if issued will increase the coverage around technologies utilizing the PD2i® Algorithm.</p>
</div>
</div>
</div>
<p>&nbsp;</p>
<p><span style="color: #800000; font-size: medium;"><strong>Scientific Advisory Board</strong></span></p>
<p>Vicor has assembled a Scientific Advisory Board consisting of medical doctors and other professionals with experience in relevant scientific and medical fields. The advisory board provides thought-leader guidance to management regarding science, research and product development.</p>
<p><strong>Edward F. Lundy,  M.D., Ph.D.</strong><br />
Chief of Cardiothoracic Surgery at Good Samaritan Hospital<br />
Ph.D. in Physiology with focus on altered-state physiologies (hibernation)</p>
<p><strong>Mark E. Josephson, M.D.</strong><br />
Chief of Cardiology at Beth Israel Deaconness Medical Center<br />
Author of “Clinical Cardiac Electrophysiology”<br />
Scientific Advisor to over 20 companies</p>
<p><strong>Hein J. J. Wellens, M.D.</strong><br />
Professor &amp; Chairman of Department of Cardiology Academisch Ziekenhuis Maastricht<br />
Director of Interuniversity Cardiology Institute of the Netherlands</p>
<p><strong>Richard M. Luceri, M.D., F.A.C.C.</strong><br />
Director Interventional Arrhythmia Center, Holy Cross Hospital<br />
Clinical investigator in MADIT II Trial<br />
Clinical investigator &amp; Principal Author SCD-HeFT Trial</p>
<p><strong>Jules Mitchel, Ph.D., MBA</strong><br />
Founder and President/CEO Target Health Inc. NYC</p>
<p><strong>Robert G. Hauser, M.D., F.A.C.C., FHRS</strong><br />
Senior Consulting Cardiologist &#8211; Minneapolis Heart Institute<br />
Chairman Cardiovascular Services Division at Abbott Northwestern Hospital<br />
Chief Executive Officer of Cardiac Pacemakers, Inc –acquired by Guidant</p>
<p><strong>Jonathan Kaplan, M.D., M.P.H.</strong><br />
Medical Director of Fidelis Care in New York<br />
Former Medical Director for Excellus Blue Cross Blue Shield</p>
<p><strong>David Chazanovitz</strong><br />
Former CEO of Cambridge Heart, Inc.</p>
<p><span style="font-size: medium; color: #800000;"><strong>Management</strong></span></p>
<div id="wp-content">
<div id="post-91">
<div>
<p><strong>David H. Fater</strong></p>
<p><strong>President and  Chief Executive Officer, Director</strong></p>
<p>Joining Vicor in 2002, Mr. Fater serves as President, Chief Executive Officer.</p>
<p>Mr. Fater is also the founder and Chief Executive Officer of ALDA  &amp; Associates International Inc., a business and financial consulting  firm providing capital formation, capital allocation, and profit  optimization services to small companies, primarily in the health care  and life sciences industries.  Since ALDA’s formation in 1993, Mr. Fater  has worked with more than 50 entrepreneur-founded companies.  As a  company senior executive, he led BMJ Medical Management, Inc.  (1997-1999) and Community Care of America (1995-1996) through the IPO  process, and led Coastal Physician Group, Inc. (1993-1995) to a NYSE  listing and $1.0 billion market capitalization.</p>
<p>Prior to forming ALDA &amp; Associates, Mr. Fater was employed by  Ernst  &amp; Young.  He completed his 24-year tenure as a Senior  International  Partner advising senior management and boards of  directors (1969-1992).</p>
<p>Mr.  Fater is a Certified Public Accountant in Georgia, Illinois,  North Carolina,  and New York.  He holds a BS in  Accounting from the  University of North Carolina.</p>
<p><strong>James E. Skinner, PhD</strong></p>
<p><strong>Interim Chairman, </strong><strong>Vice President, Director of Grant Research, Director</strong></p>
<p>Founding Vicor in August, 2000, Dr. Skinner has extensive experience both as a scientist and manager of large research and development projects. He is the Director of the Delaware Water Gap Science Institute, a non-profit medical research organization devoted to the development of medical devices and pharmaceuticals. Prior to founding the Delaware Water Gap Science Institute, Dr. Skinner was Associate Director of Totts Gap Medical Research Laboratories, Inc. (1969-1997). Earlier, he was a Professor and Researcher at Baylor College of Medicine in Houston (1969-1993) and recipient of numerous research grants from the National Institutes of Health.</p>
<p>Dr. Skinner holds a PhD in Neuroscience from the University of California at Los Angeles and a BA in Pre-Med, Physics, and Physiological Psychology from Pomona College.</p>
<p><strong>Jerry M. Anchin, PhD</strong></p>
<p><strong>Vice President, Director of  Product Development, Director</strong></p>
<p>Dr. Anchin has more than 30 years of experience in the fields of  immunology,  molecular biology, drug discovery, and protein chemistry.   Prior to joining Vicor in 2000, Dr. Anchin was  employed by Ciblex  Pharmaceuticals (1998-2000), where he became group leader of  the drug  discovery program that led to the discovery of novel small molecules  used  in the prevention of asthma.   Earlier, he held positions at Prism  Pharmaceuticals (1996-1998), and  Immuno Pharmaceuticals (1993-1996).    Before that, he was Head of Assay Development and Manufacturing at   International Immunoassay Labs (1991-1998), where he was instrumental in   designing a novel assay for the detection of the protein creatine  kinase  released during acute myocardial infarction.</p>
<p>Dr. Anchin holds patents for 14 immunoassay and drug discovery  platforms; he has an  additional 16 patents pending.  Dr.  Anchin earned  a PhD in Immunology from Texas A&amp;M University and a BA in  Cell  Biology from the University of California at Santa Barbara.</p>
<p><strong>Daniel N. Weiss, MD, FACC</strong></p>
<p><strong>Chief Medical Officer</strong></p>
<p>With Vicor since 2004, Dr. Weiss has extensive experience in the  practice of cardiology and electrophysiology.  Dr. Weiss is a partner  with Florida Arrythmia Consultants and a former director of the Jim  Moran Heart and Vascular Center.  He has served as a consultant to <em>Fortune</em> 500 medical device manufacturers, including  Medtronics, St. Jude  Medical, and Guidant.  He also served as the clinical investigator on  the two most important clinical trials involving the study of ICDs and  SCD (MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial)  and SCD HeFT (Sudden Cardiac Death Heart Failure Trial).</p>
<p>Dr. Weiss received a MD with Distinction in Research from the Mount  Sinai School of Medicine, from which he also received the Nathan A. Setz  Award for Research in Cardiovascular and Renal Disease.  He holds a BSE  cum laude in Electrical Engineering and Computer Science from Princeton  University.</p>
<p><strong>Richard M. Cohen, PhD</strong></p>
<p><strong>Vice President of Corporate and Business Development, Chief Operating Officer</strong></p>
<p>Richard Cohen was appointed to serve as Vice President of Business  Development on January 1, 2008. Since 2001, Dr. Cohen has been the Chief  Operating Officer of ALDA &amp; Associates International, Inc., a  business and consulting firm providing capital formation, capital  allocation, and profit optimization services to small companies,  primarily in the healthcare and life sciences industries. In his  capacity as ALDA’s Chief Operating Officer and in connection with  certain consulting engagements, Dr. Cohen has served as the Chief  Executive Officer of two healthcare companies and two medical device  companies. He has more than 30 years of experience in international  manufacturing and operations, predominantly in the Far East and South  America.</p>
<p>Dr. Cohen holds a PhD in International Business from Buxton  University and a BS in Business Marketing from Kentucky Wesleyan  University.</p>
<p><strong>Thomas J. Bohannon, CPA</strong></p>
<p><strong>Chief Financial Officer, Chief Accounting Officer</strong></p>
<p>Mr. Bohannon was appointed to serve as the Chief Accounting Officer  of the Company effective December 28, 2008. Mr. Bohannon has been in the  accounting and financial field for more than 40 years. Prior to joining  Vicor, Mr. Bohannon ran an independent consulting practice from which  he served as financial officer for a variety of companies in the  Southeast United States.  Earlier, he was partner in charge of audit and  review services for Pappadakis, Nelson &amp; Bohannon (1978—1991).   Before that, he was a senior manager specializing in financial and SEC  reporting at Ernst &amp; Young in Atlanta.</p>
</div>
<div><span style="font-size: medium; color: #800000;"><strong>Board of Directors</strong></span></div>
<div>
<div id="wp-content">
<div id="post-94">
<div>
<p>The current directors of the Company are David H. Fater (2002)  and James E. Skinner (2000) (Class I), Jerry M. Anchin (2003) and  Frederick M. Hudson (2008) (Class II), and Joseph C. Franchetti (2008),  Ronald A. Malone (2010), and Frank B. Wheeler (2010)  (Class III). The  Class I Directors’ term expires at the 2011 Annual Meeting. The Class II  Directors’ term expires at the 2012 Annual Meeting. The Class III  Directors’ term  expires at the 2013 Annual Meeting.</p>
<p><strong>Frederick M. Hudson</strong></p>
<p>At the time of his retirement from KPMG, Mr. Hudson was a partner  in  charge of the firm’s Mid-Atlantic Health  Care Practice (1969-2006).   He is a  Director on the Board of Financial Administration of the  Catholic Archdiocese  of Baltimore, the Board of Sponsors of Loyola  College Sellinger School of  Business and Management, and the Board of  Trustees of the Maryland Historical  Society.  He is Chairman of the  Audit  Committee of the Board of Directors of Paradigm Management  Services, LLC, and  Remedi Health Services, Inc., and a member of the  Audit and Finance Committee  of the Board of Directors of GBMC  Healthcare, Inc., and its affiliate, the  Greater Baltimore Medical  Center.  Mr.  Hudson is a graduate of Loyola College.</p>
<p><strong>Joseph C. Franchetti</strong></p>
<p>Mr. Franchetti has been on the board since 2008.  He is, and has been, a consultant, director, and advisor to several healthcare/medical device companies, including start-ups, in the cardiology/cardiovascular and life sciences areas. He is currently Vice Chairman of CVAC Health Systems, Inc. Earlier, he was President and Chief Executive Officer of Cohn Medical Instruments Corp. (now Omron),<strong> </strong>a Japanese-owned, global leader in non-invasive blood pressure, and physiological and vital sign monitoring and diagnosis. He founded and was Chief Executive Officer of Bio-Chem Laboratory Systems Inc., and a Corporate and International Vice President and General Manager for Technicon (now Siemens) and Narco Scientific (now Respirionics). He is a Trustee Emeritus of Southwest Research Institute of Texas. Mr. Franchetti is a graduate of the Wharton School of the University of Pennsylvania.</p>
<p><strong>Ronald A. Malone</strong></p>
<p>Ronald A. Malone is the former chief executive officer (6/02-9/08)  and current chairman of the Board (6/02-present) of Gentiva Health  Services, Inc., the leading provider of home healthcare services in the  U.S.  Earlier, Mr. Malone served in various executive positions at  Gentiva (3/00-6/02).  Prior to joining Gentiva, Mr. Malone held various  executive positions with Olsten Corporation, a world leader in staffing  services and the leading provider of home healthcare and related  services in North America.  Mr. Malone also serves on the Board of  Directors of Hill-Rom Holdings, Inc., a worldwide manufacturer and  provider of medical technologies and related services for the healthcare  industry, and Capital Senior Living Corporation, a leading operator of  senior living communities in the U.S.  Mr. Malone holds a bachelors  degree from Furman University.</p>
<p><strong>Frank B. Wheeler</strong></p>
<p>Former Ambassador Frank B. Wheeler is an  independent business   consultant involved with health insurance and  software companies.  He   currently serves as chairman of the  British-Chilean Chamber of Commerce   in London, and was international  adviser to the English Football   Association in its campaign to host the  2006 World Cup. Mr. Wheeler was  a  member of the British Diplomatic  Service for 35 years until his   retirement in 1997.  During his tenure,  he was Ambassador to Chile and   Ecuador, Charge d’Affairs in  Czechoslovakia, and foreign policy  adviser  on East-West affairs and  Middle East issues. Mr. Wheeler holds  an  Advanced Level Certificate in  French and German from the Mill Hill   School in London.  He is a  graduate in Russian Studies from the Joint   Services College for  Linguists and obtained Diploma in Economics from   the Treasury Centre  for Administrative Studies in London.</p>
</div>
</div>
</div>
</div>
</div>
</div>
<p><strong>Contact:<br />
David H. Fater, CEO<br />
</strong>Vicor Technologies, Inc.<br />
561.995.7313<br />
dfater@vicortech.com</p>
<p>Caution Regarding Forward-Looking Statements Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i(R) values; our ability to generate revenues from the sale of the PD2i Analyzer(TM); our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer(TM); our ability to develop additional applications for the PD2i Analyzer(TM); our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ  Disclaimer The appearance of name-brand institutions, such as the American College of Cardiology, the Heart Research Follow-up Program at the University of Rochester Medical Center and Active International Cardiovascular Institute at Good Samaritan Hospital, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.</p>
<p>&nbsp;</p>
<p>VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly.  The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares.  To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable.  In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended.   In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2011/06/vicor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vicor Technologies, Inc. (OTCBB: VCRT)</title>
		<link>http://www.shareholdervision.com/2010/04/vicor-fater/</link>
		<comments>http://www.shareholdervision.com/2010/04/vicor-fater/#comments</comments>
		<pubDate>Thu, 08 Apr 2010 03:10:30 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[VCRT]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/?p=240</guid>
		<description><![CDATA[We invite you to view our interview with David Fater, Chairman, President and CEO of Vicor Technologies.  ]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/240.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<p><span style="font-family: times new roman,times;"><span style="font-size: medium;"><strong>Vicor Technologies, Inc.<br />
Website: </strong><a href="http://vicortech.com">http://www.VicorTech.com</a><br />
2300 NW Corporate Blvd. Suite 123<br />
Boca Raton, FL  33431<br />
Phone: 877-528-PD2i (7324)</span></span></p>
<p><strong><br />
</strong></p>
<p><img src="http://www.sguru.co/lt/VCRT/logo450.png" alt="" /></p>
<p><span style="color: #800000;"><strong><span style="font-size: medium;">Vicor Technologies, Inc. (OTCBB: VCRT) </span></strong></span>is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i <sup>® </sup>Algorithm and software.</p>
<p>With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.</p>
<p>The Company has all of the regulatory approvals in place already with regards to PD2i <sup>® </sup>to generate substantial revenues.</p>
<p><span style="font-size: medium; color: #800000;"><strong>FDA Approval of PD2i Analyzer™ for BOTH Heart Rate Variability and Cardiovascular Disease Testing</strong></span></p>
<p>Vicor’s PD2i Analyzer™ has FDA 510(k) marketing clearance to both:</p>
<ul>
<li>Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.</li>
<li>And be used specifically in patients undergoing cardiovascular disease testing.</li>
</ul>
<p><span style="font-size: medium; color: #800000;"><strong>Potential Market PD2i Analyzer™</strong></span></p>
<p>The potential market for the PD2i Analyzer™ with 77 million potential patients could be in the multi-billions of dollars.  This market is supported by the recent FDA approval to market the PD2i Analyzer™  for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer™ as a valuable new diagnostic.</p>
<p>The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i<sup>® </sup><sup> </sup>metric includes the classical Ewing maneuvers with the PD2i<sup>® </sup>metric in patients undergoing cardiovascular disease testing.</p>
<p>This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i <sup>® </sup>technology by Vicor in 2003.</p>
<p><img src="http://www.sguru.co/lt/VCRT/ppt2.jpg" alt="" /></p>
<p>These populations are significant:</p>
<ul>
<li>23.6 million diabetics</li>
<li>15 million at-risk cardiac patients</li>
<li>38 million trauma incidents</li>
</ul>
<p><span style="font-size: medium; color: #800000;"><strong>PD2i <sup>® </sup>Analyzer </strong><strong>Provides Additional Revenue Source for Physicians and Improves Patient Care</strong></span></p>
<p>Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.</p>
<p>Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.  Physicians are able to use the Analyzer for indications believed to be useful.  FDA clearance of specific indications allows Vicor to explicitly market for those indications.</p>
<p>Current procedural terminology (CPT) codes enable physicians using the PD2i<sup>® </sup> Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.</p>
<p>The PD2i<sup>® </sup> Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.</p>
<p>The PD2i <sup>® </sup>Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.</p>
<p><img src="http://www.sguru.co/lt/VCRT/ppt1.jpg" alt="" /></p>
<p><span style="font-size: medium; color: #800000;"><strong>PD2i </strong><strong><sup>® </sup>Algorithm New and Accurate Vital Sign</strong></span></p>
<p>The Company believes that the PD2i <sup>® </sup>Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.</p>
<p><span style="background-color: #ffffff;">Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i <sup>® </sup>Algorithm: </span></p>
<ul>
<li>First &#8211; the PD2i<sup>® </sup> Analyzer</li>
<li>Second - the PD2i Cardiac Analyzer ™</li>
<li>The PD2i VS ™ Vital Sign Monitor for trauma, triage, and other hospital uses in still  under development.</li>
</ul>
<p>&nbsp;</p>
<p><span style="color: #800000; font-size: medium;"><strong>FDA Clearance</strong></span></p>
<p>In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i<sup>® </sup> nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.</p>
<p>Physician use of the PD2i<sup>® </sup> Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i<sup>® </sup> nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.</p>
<p><img src="http://www.sguru.co/lt/VCRT/11.jpg" alt="" width="189" height="126" /></p>
<p><span style="font-size: medium; color: #800000;"><strong>Physician Use Includes :</strong></span></p>
<ul>
<li>Diabetics for the presence of diabetic autonomic neuropathy (DAN),</li>
<li>Cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and</li>
<li>Trauma victims for imminent death absent immediate lifesaving intervention.</li>
</ul>
<p><span style="font-size: medium; color: #800000;"><strong>Sales</strong></span></p>
<p>The Company has engaged various independent sales agents and sales representatives to market and sell its products in selected geographic areas in the United States.</p>
<p>Revenues will be predominately the result of equipment sales, fees from physicians and other health-care providers related to the analysis of test results and licensing fees.</p>
<p><img src="http://www.sguru.co/lt/VCRT/analyzer.jpg" alt="" /><br />
<img src="http://sguru.co/l/vcrt/result-1.png" alt="" width="354" height="411" /></p>
<p>&nbsp;</p>
<p><img src="http://sguru.co/l/vcrt/result-2.png" alt="" width="366" height="400" /></p>
<p>&nbsp;</p>
<p><img src="http://sguru.co/l/vcrt/result-3.png" alt="" width="468" height="393" /></p>
<p style="padding-left: 30px;"><strong> </strong></p>
<p><span style="font-size: medium; color: #800000;"><strong>Revenue Sources</strong></span></p>
<p>A national sales manager with a long and successful history in   medical device sales has been retained.  The sales force has expanded   geographically.  Vicor expects to continue to increase the size of its   domestic sales force throughout 2011, to approximately 70 Sales   Representatives by the end of 2011</p>
<p style="padding-left: 30px;"><strong>Equipment sales:</strong> Sales to physicians and other health care providers through both sales   representatives employed by the Company and also independent sales   agents.</p>
<p style="padding-left: 30px;"><strong>Leasing option:</strong> Agreement with equipment leasing company signed in early 2011 allows physicians to obtain the Analyzer without the upfront cost.</p>
<p style="padding-left: 30px;"><strong>International Distribution:</strong> An agreement with a distributor for Asia and Israel has been reached.  Vicor  currently is negotiating contracts for distribution in Middle East and  Europe.</p>
<p style="padding-left: 30px;"><strong>Current procedural terminology: (CPT) codes </strong>enable physicians using  the PD2i<sup>® </sup> Analyzer to measure HRV to be reimbursed by insurance  carriers, creating a recurring source of revenue from test analysis for  Vicor.</p>
<p><span style="font-size: medium; color: #800000;"><strong>Direct Marketing to Cardiologists</strong></span></p>
<p>FDA approval enables Vicor to market the PD2i<sup>® </sup> Analyzer directly to cardiologists as a diagnostic specifically targeted for use in cardiovascular disease testing.</p>
<p>VCRT is focused on spurring market acceptance of the PD2i<sup>® </sup> Analyzer as a valuable new diagnostic for cardiovascular disease testing.</p>
<p>Including the Ewing Maneuvers which are performed during PD2i Analyzer™ ECG data collection.</p>
<p>This recognition represents the PD2i<sup>® </sup> Analyzer as a meaningful metric for cardiovascular testing and validation of, from a regulatory perspective, our use of the Internet for the delivery of test data and analyses.</p>
<p>While cardiologists are already among users of the PD2i<sup>® </sup> Analyzer as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health, the Company anticipates this new clearance will contribute positively to the cardiologist-directed marketing efforts of the PD2i<sup>® </sup> Analyzer.</p>
<p><span style="color: #800000; font-size: medium;"><strong>Plan of Operations </strong></span></p>
<p style="padding-left: 30px;">1.   Increasing sales of the PD2i<sup>® </sup> Analyzer to physicians and health care facilities in the United States through the use of independent sales agents and direct sales personnel.</p>
<p style="padding-left: 30px;">2.     Raising additional capital with which to expand the sales and administrative infrastructure and fund ongoing operations until our operations generate positive cash flow.</p>
<p style="padding-left: 30px;">3.      Completing various clinical trials and 510(k) submissions to secure additional marketing claims for the PD2i<sup>® </sup> Analyzer to enhance and accelerate marketing efforts.</p>
<p style="padding-left: 30px;">4.      Initiating international sales of the PD2i<sup>® </sup> Analyzer and PD2i-VS<sup>® </sup> (Vital Sign), including securing CE Mark Clearance.</p>
<p>Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or resulting from inaccurate identification are garnering increased attention in the current health care reform environment.</p>
<p><span style="font-size: medium; color: #800000;"><strong>Conference Exposure</strong></span></p>
<p>Exposure through presentations at prestigious events and publication  in prominent journals is one of the most influential forms of marketing  and Vicor has extensive participation conference plans for 2011.</p>
<p>This direct exposure to physicians and the medical community represents a potential catalyst for sales and growth.</p>
<p>&nbsp;</p>
<p><span style="font-size: medium; color: #800000;"><strong>The Company has attended recent conferences including:</strong></span></p>
<ul>
<li>The American Heart Association in November of 2010</li>
<li>The American College of Cardiology in April of 2011.  One of Vicor&#8217;s congestive heart failure studies was presented by the researcher.</li>
<li>Vicor was just in attendance at the Heart Rhythes Society Conference in May</li>
<li>Vicor&#8217;s Chief Medical Officer is due to make a presentation to the Israeli Trauma Society meeting this summer.</li>
</ul>
<p>&nbsp;</p>
<p><span style="color: #800000; font-size: medium;"><strong>Clinical Studies</strong></span></p>
<p>Clinical studies completed or initiated have been conclusive concerning the ability of the PD2i <sup>® </sup>metric to be predictive of future pathological events.</p>
<p>This is of great significance to the medical community in terms of enabling physicians to easily risk stratify their patients as well as use these results to better manage their care.</p>
<p>The body of literature documenting the PD2i(R) nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events is constantly expanding.</p>
<p>Over 60 published manuscripts exist regarding the use of the PD2i<sup>® </sup>by physicians and scientists around the world in a multitude of disease states and modalities exist . Many of the researchers are well published and respected internationally.</p>
<p>These independent studies, which are not for FDA-approved indications, include the use of Vicor&#8217;s PD2i<sup>® </sup> nonlinear algorithm to:</p>
<ul>
<li><span style="background-color: #ffffff;">Predict seizure</span></li>
<li><span style="background-color: #ffffff;">Monitor transplant rejection</span></li>
<li><span style="background-color: #ffffff;">Analyze ventricular fibrillation</span></li>
<li><span style="background-color: #ffffff;">Identify depression</span></li>
<li><span style="background-color: #ffffff;">Determine risk in Sleep apnea</span></li>
<li><span style="background-color: #ffffff;">Autoimmune system imbalance detection</span></li>
<li><span style="background-color: #ffffff;">See the increased neural complexity in schizophrenic patients</span></li>
<li><span style="background-color: #ffffff;">Determine the impact of ECT therapy on depression</span></li>
<li><span style="background-color: #ffffff;">Monitor the effect of estrogen and testosterone on  convergent and divergent thinking</span></li>
<li><span style="background-color: #ffffff;">Locate seizure focus for epileptic surgery.</span></li>
</ul>
<p>These independent studies attest that Vicor&#8217;s PD2i<sup>® </sup> nonlinear algorithm has successfully demonstrated the ability to accurately measure heart rate variability to predict and identify a variety of medical conditions and disorders.</p>
<p>The range of human conditions and disorders that can be identified early in their arc and thereby provide physicians with the ability to enhance patient treatment and outcomes.</p>
<p>Continuing clinical studies are ongoing in a variety of areas &#8212; chief among these, sudden cardiac death and head trauma in athletes &#8212; to establish the PD2i<sup>® </sup>Analyzer as a widely used diagnostic in the clinical setting.</p>
<p>&nbsp;</p>
<div id="wp-content">
<div id="post-100">
<div>
<p><span style="color: #800000; font-size: medium;"><strong>Patent and Proprietary Rights</strong></span></p>
<p>Vicor has issued patents covering the core systems with the PD2i® Algorithm and methods of identifying biological anomalies using this algorithm as well as issued patents covering machines and methods for data manipulation for use with the PD2i® Algorithm from United States of America (5,709,214), United States of America (5,720,294), Azerbaijan (008979), Armenia (008979), Belarus (008979), Kazakhstan (008979), Kyrgyzstan (008979), Moldova, Republic of (008979), New Zealand (54202), Russian Federation (008979), South Africa (2005/06909), Tajikistan (008979), Turkmenistan (008979), United States of America (7,076,288) and United States of America (7,276,026). It has been allowed in Australia (Australian Patent Application 2004208161) and Israel (Israel Patent Application 169988). There are also a number of patent applications around the world covering additional aspects and uses of the PD2i® technology, which if issued will increase the coverage around technologies utilizing the PD2i® Algorithm.</p>
</div>
</div>
</div>
<p>&nbsp;</p>
<p><span style="color: #800000; font-size: medium;"><strong>Scientific Advisory Board</strong></span></p>
<p>Vicor has assembled a Scientific Advisory Board consisting of medical doctors and other professionals with experience in relevant scientific and medical fields. The advisory board provides thought-leader guidance to management regarding science, research and product development.</p>
<p><strong>Edward F. Lundy,  M.D., Ph.D.</strong><br />
Chief of Cardiothoracic Surgery at Good Samaritan Hospital<br />
Ph.D. in Physiology with focus on altered-state physiologies (hibernation)</p>
<p><strong>Mark E. Josephson, M.D.</strong><br />
Chief of Cardiology at Beth Israel Deaconness Medical Center<br />
Author of “Clinical Cardiac Electrophysiology”<br />
Scientific Advisor to over 20 companies</p>
<p><strong>Hein J. J. Wellens, M.D.</strong><br />
Professor &amp; Chairman of Department of Cardiology Academisch Ziekenhuis Maastricht<br />
Director of Interuniversity Cardiology Institute of the Netherlands</p>
<p><strong>Richard M. Luceri, M.D., F.A.C.C.</strong><br />
Director Interventional Arrhythmia Center, Holy Cross Hospital<br />
Clinical investigator in MADIT II Trial<br />
Clinical investigator &amp; Principal Author SCD-HeFT Trial</p>
<p><strong>Jules Mitchel, Ph.D., MBA</strong><br />
Founder and President/CEO Target Health Inc. NYC</p>
<p><strong>Robert G. Hauser, M.D., F.A.C.C., FHRS</strong><br />
Senior Consulting Cardiologist &#8211; Minneapolis Heart Institute<br />
Chairman Cardiovascular Services Division at Abbott Northwestern Hospital<br />
Chief Executive Officer of Cardiac Pacemakers, Inc –acquired by Guidant</p>
<p><strong>Jonathan Kaplan, M.D., M.P.H.</strong><br />
Medical Director of Fidelis Care in New York<br />
Former Medical Director for Excellus Blue Cross Blue Shield</p>
<p><strong>David Chazanovitz</strong><br />
Former CEO of Cambridge Heart, Inc.</p>
<p><span style="font-size: medium; color: #800000;"><strong>Management</strong></span></p>
<div id="wp-content">
<div id="post-91">
<div>
<p><strong>David H. Fater</strong></p>
<p><strong>President and  Chief Executive Officer, Director</strong></p>
<p>Joining Vicor in 2002, Mr. Fater serves as President, Chief Executive Officer.</p>
<p>Mr. Fater is also the founder and Chief Executive Officer of ALDA  &amp; Associates International Inc., a business and financial consulting  firm providing capital formation, capital allocation, and profit  optimization services to small companies, primarily in the health care  and life sciences industries.  Since ALDA’s formation in 1993, Mr. Fater  has worked with more than 50 entrepreneur-founded companies.  As a  company senior executive, he led BMJ Medical Management, Inc.  (1997-1999) and Community Care of America (1995-1996) through the IPO  process, and led Coastal Physician Group, Inc. (1993-1995) to a NYSE  listing and $1.0 billion market capitalization.</p>
<p>Prior to forming ALDA &amp; Associates, Mr. Fater was employed by  Ernst  &amp; Young.  He completed his 24-year tenure as a Senior  International  Partner advising senior management and boards of  directors (1969-1992).</p>
<p>Mr.  Fater is a Certified Public Accountant in Georgia, Illinois,  North Carolina,  and New York.  He holds a BS in  Accounting from the  University of North Carolina.</p>
<p><strong>James E. Skinner, PhD</strong></p>
<p><strong>Interim Chairman, </strong><strong>Vice President, Director of Grant Research, Director</strong></p>
<p>Founding Vicor in August, 2000, Dr. Skinner has extensive experience both as a scientist and manager of large research and development projects. He is the Director of the Delaware Water Gap Science Institute, a non-profit medical research organization devoted to the development of medical devices and pharmaceuticals. Prior to founding the Delaware Water Gap Science Institute, Dr. Skinner was Associate Director of Totts Gap Medical Research Laboratories, Inc. (1969-1997). Earlier, he was a Professor and Researcher at Baylor College of Medicine in Houston (1969-1993) and recipient of numerous research grants from the National Institutes of Health.</p>
<p>Dr. Skinner holds a PhD in Neuroscience from the University of California at Los Angeles and a BA in Pre-Med, Physics, and Physiological Psychology from Pomona College.</p>
<p><strong>Jerry M. Anchin, PhD</strong></p>
<p><strong>Vice President, Director of  Product Development, Director</strong></p>
<p>Dr. Anchin has more than 30 years of experience in the fields of  immunology,  molecular biology, drug discovery, and protein chemistry.   Prior to joining Vicor in 2000, Dr. Anchin was  employed by Ciblex  Pharmaceuticals (1998-2000), where he became group leader of  the drug  discovery program that led to the discovery of novel small molecules  used  in the prevention of asthma.   Earlier, he held positions at Prism  Pharmaceuticals (1996-1998), and  Immuno Pharmaceuticals (1993-1996).    Before that, he was Head of Assay Development and Manufacturing at   International Immunoassay Labs (1991-1998), where he was instrumental in   designing a novel assay for the detection of the protein creatine  kinase  released during acute myocardial infarction.</p>
<p>Dr. Anchin holds patents for 14 immunoassay and drug discovery  platforms; he has an  additional 16 patents pending.  Dr.  Anchin earned  a PhD in Immunology from Texas A&amp;M University and a BA in  Cell  Biology from the University of California at Santa Barbara.</p>
<p><strong>Daniel N. Weiss, MD, FACC</strong></p>
<p><strong>Chief Medical Officer</strong></p>
<p>With Vicor since 2004, Dr. Weiss has extensive experience in the  practice of cardiology and electrophysiology.  Dr. Weiss is a partner  with Florida Arrythmia Consultants and a former director of the Jim  Moran Heart and Vascular Center.  He has served as a consultant to <em>Fortune</em> 500 medical device manufacturers, including  Medtronics, St. Jude  Medical, and Guidant.  He also served as the clinical investigator on  the two most important clinical trials involving the study of ICDs and  SCD (MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial)  and SCD HeFT (Sudden Cardiac Death Heart Failure Trial).</p>
<p>Dr. Weiss received a MD with Distinction in Research from the Mount  Sinai School of Medicine, from which he also received the Nathan A. Setz  Award for Research in Cardiovascular and Renal Disease.  He holds a BSE  cum laude in Electrical Engineering and Computer Science from Princeton  University.</p>
<p><strong>Richard M. Cohen, PhD</strong></p>
<p><strong>Vice President of Corporate and Business Development, Chief Operating Officer</strong></p>
<p>Richard Cohen was appointed to serve as Vice President of Business  Development on January 1, 2008. Since 2001, Dr. Cohen has been the Chief  Operating Officer of ALDA &amp; Associates International, Inc., a  business and consulting firm providing capital formation, capital  allocation, and profit optimization services to small companies,  primarily in the healthcare and life sciences industries. In his  capacity as ALDA’s Chief Operating Officer and in connection with  certain consulting engagements, Dr. Cohen has served as the Chief  Executive Officer of two healthcare companies and two medical device  companies. He has more than 30 years of experience in international  manufacturing and operations, predominantly in the Far East and South  America.</p>
<p>Dr. Cohen holds a PhD in International Business from Buxton  University and a BS in Business Marketing from Kentucky Wesleyan  University.</p>
<p><strong>Thomas J. Bohannon, CPA</strong></p>
<p><strong>Chief Financial Officer, Chief Accounting Officer</strong></p>
<p>Mr. Bohannon was appointed to serve as the Chief Accounting Officer  of the Company effective December 28, 2008. Mr. Bohannon has been in the  accounting and financial field for more than 40 years. Prior to joining  Vicor, Mr. Bohannon ran an independent consulting practice from which  he served as financial officer for a variety of companies in the  Southeast United States.  Earlier, he was partner in charge of audit and  review services for Pappadakis, Nelson &amp; Bohannon (1978—1991).   Before that, he was a senior manager specializing in financial and SEC  reporting at Ernst &amp; Young in Atlanta.</p>
</div>
<div><span style="font-size: medium; color: #800000;"><strong>Board of Directors</strong></span></div>
<div>
<div id="wp-content">
<div id="post-94">
<div>
<p>The current directors of the Company are David H. Fater (2002)  and James E. Skinner (2000) (Class I), Jerry M. Anchin (2003) and  Frederick M. Hudson (2008) (Class II), and Joseph C. Franchetti (2008),  Ronald A. Malone (2010), and Frank B. Wheeler (2010)  (Class III). The  Class I Directors’ term expires at the 2011 Annual Meeting. The Class II  Directors’ term expires at the 2012 Annual Meeting. The Class III  Directors’ term  expires at the 2013 Annual Meeting.</p>
<p><strong>Frederick M. Hudson</strong></p>
<p>At the time of his retirement from KPMG, Mr. Hudson was a partner  in  charge of the firm’s Mid-Atlantic Health  Care Practice (1969-2006).   He is a  Director on the Board of Financial Administration of the  Catholic Archdiocese  of Baltimore, the Board of Sponsors of Loyola  College Sellinger School of  Business and Management, and the Board of  Trustees of the Maryland Historical  Society.  He is Chairman of the  Audit  Committee of the Board of Directors of Paradigm Management  Services, LLC, and  Remedi Health Services, Inc., and a member of the  Audit and Finance Committee  of the Board of Directors of GBMC  Healthcare, Inc., and its affiliate, the  Greater Baltimore Medical  Center.  Mr.  Hudson is a graduate of Loyola College.</p>
<p><strong>Joseph C. Franchetti</strong></p>
<p>Mr. Franchetti has been on the board since 2008.  He is, and has been, a consultant, director, and advisor to several healthcare/medical device companies, including start-ups, in the cardiology/cardiovascular and life sciences areas. He is currently Vice Chairman of CVAC Health Systems, Inc. Earlier, he was President and Chief Executive Officer of Cohn Medical Instruments Corp. (now Omron),<strong> </strong>a Japanese-owned, global leader in non-invasive blood pressure, and physiological and vital sign monitoring and diagnosis. He founded and was Chief Executive Officer of Bio-Chem Laboratory Systems Inc., and a Corporate and International Vice President and General Manager for Technicon (now Siemens) and Narco Scientific (now Respirionics). He is a Trustee Emeritus of Southwest Research Institute of Texas. Mr. Franchetti is a graduate of the Wharton School of the University of Pennsylvania.</p>
<p><strong>Ronald A. Malone</strong></p>
<p>Ronald A. Malone is the former chief executive officer (6/02-9/08)  and current chairman of the Board (6/02-present) of Gentiva Health  Services, Inc., the leading provider of home healthcare services in the  U.S.  Earlier, Mr. Malone served in various executive positions at  Gentiva (3/00-6/02).  Prior to joining Gentiva, Mr. Malone held various  executive positions with Olsten Corporation, a world leader in staffing  services and the leading provider of home healthcare and related  services in North America.  Mr. Malone also serves on the Board of  Directors of Hill-Rom Holdings, Inc., a worldwide manufacturer and  provider of medical technologies and related services for the healthcare  industry, and Capital Senior Living Corporation, a leading operator of  senior living communities in the U.S.  Mr. Malone holds a bachelors  degree from Furman University.</p>
<p><strong>Frank B. Wheeler</strong></p>
<p>Former Ambassador Frank B. Wheeler is an  independent business   consultant involved with health insurance and  software companies.  He   currently serves as chairman of the  British-Chilean Chamber of Commerce   in London, and was international  adviser to the English Football   Association in its campaign to host the  2006 World Cup. Mr. Wheeler was  a  member of the British Diplomatic  Service for 35 years until his   retirement in 1997.  During his tenure,  he was Ambassador to Chile and   Ecuador, Charge d’Affairs in  Czechoslovakia, and foreign policy  adviser  on East-West affairs and  Middle East issues. Mr. Wheeler holds  an  Advanced Level Certificate in  French and German from the Mill Hill   School in London.  He is a  graduate in Russian Studies from the Joint   Services College for  Linguists and obtained Diploma in Economics from   the Treasury Centre  for Administrative Studies in London.</p>
</div>
</div>
</div>
</div>
</div>
</div>
<p><strong>Contact:<br />
David H. Fater, CEO<br />
</strong>Vicor Technologies, Inc.<br />
561.995.7313<br />
dfater@vicortech.com</p>
<p>Caution Regarding Forward-Looking Statements Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i(R) values; our ability to generate revenues from the sale of the PD2i Analyzer(TM); our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer(TM); our ability to develop additional applications for the PD2i Analyzer(TM); our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ  Disclaimer The appearance of name-brand institutions, such as the American College of Cardiology, the Heart Research Follow-up Program at the University of Rochester Medical Center and Active International Cardiovascular Institute at Good Samaritan Hospital, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.</p>
<p>&nbsp;</p>
<p>VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly.  The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares.  To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable.  In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended.   In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/04/vicor-fater/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Halo Companies, Inc.  (OTCBB: HALN)</title>
		<link>http://www.shareholdervision.com/2010/03/haln-overview/</link>
		<comments>http://www.shareholdervision.com/2010/03/haln-overview/#comments</comments>
		<pubDate>Mon, 15 Mar 2010 22:32:54 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[HALN]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/?p=134</guid>
		<description><![CDATA[Halo Companies, Inc. (OTCBB: HALN)  is a nationwide holding company based in Allen, TX with eleven subsidiaries that operate primarily in the consumer financial services industry including:
Debt, Mortgage, Real Estate, Credit, Loan Modification and Insurance.]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/134.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<p><strong>Halo Companies, Inc.<br />
<span style="font-family: 'arial black', 'avant garde';"> Website: </span></strong><a href="http://haloco.com"><span style="font-family: 'arial black', 'avant garde';">http://www.HaloCo.Com</span><br />
</a><br />
One Allen Center<br />
Suite 500<br />
700 Central Expressway South<br />
Allen, TX 75013<br />
Phone: 214-644-0065</p>
<p><strong>About Halo Companies, Inc.</strong></p>
<p>Halo Companies, Inc. is a nationwide holding company based in Allen, TX with eleven subsidiaries that operate primarily in the consumer financial services industry including debt, mortgage, real estate, credit, loan modification, insurance and portfolio advisors. Halo has been recently recognized by Inc. Magazine, Comerica Bank&#8217;s Collin 60, and the SMU Cox School of Business Dallas 100. For more information about Halo Companies, Inc., visit www.haloco.com.</p>
<p><img src="http://stockguru.com/lt/GPAX/halolog.jpg" alt="" width="450" height="147" /></p>
<p><strong>Halo Companies, Inc.</strong></p>
<p><strong>Website: </strong><a href="http://haloco.com"><strong>http://haloco.com</strong></a></p>
<p>Understand the Issues. Create a plan. Obtain the Best People. Manage the Growth.</p>
<p><strong>Halo Companies, Inc. (OTCBB: HALN)</strong> (“Halo Companies” – “Halo”) understands the financial issues Americans are facing at a time, when for many, the American dream has become the American nightmare. The country of easy credit, rising home values, stable retirement investment accounts and 4.4 million jobs no longer exists. That’s over. That’s History.</p>
<p>Halo Companies is composed of twelve companies and over 100 employees assisting consumers in achieving their financial goals.</p>
<p><img src="http://stockguru.com/lt/GPAX/wideexterior.jpg" alt="" width="460" height="216" /></p>
<p>Halo diversifies its business into two categories:</p>
<ul>
<li>Origination: such as mortgage, insurance and residential real estate services</li>
<li>Mitigation: including debt settlement, loan modification and credit repair services</li>
</ul>
<p>Founded in 2004, Halo achieved right at $5 Million dollars in revenue in 2008, which represents a stunning growth of 506%. In an economy where many companies are struggling to maintain status quo, Halo continues to thrive. The numbers show, as a result of these challenging financial times, more and more people seek professional advice and solutions where their money is concerned.</p>
<p><img src="http://stockguru.com/lt/GPAX/QuarterlyGrossRevenue1.jpg" alt="" width="482" height="290" /></p>
<p>Halo’s growth is confirmation of the performance of its unprecedented and effective business model.</p>
<p>Halo&#8217;s full suite of services provide assistance to consumers in times of financial distress. These services include mortgage loan modification, unsecured debt resolution and credit management. Additionally, Halo offers mortgage lending, real estate representation, and insurance protection to help each consumer accomplish the dream of homeownership.</p>
<p><img src="http://www.stockguru.com/l/gpax/gpax-chart.png" alt="" width="536" height="1161" /></p>
<p><strong>Halo Companies, Inc. Meets Huge Demand for Broad Based Financial Services</strong></p>
<p>As middle-class as McDonald’s, as technologically savvy as E-Trade, as ubiquitous as UPS, and as astute as Goldman-Sachs: Halo Companies emerges on the financial horizon with the ONLY stable and complete solution for combating the greatest threat to American home ownership and the very financial engine of the middle-class.</p>
<p>The Company represents precisely what smart business people do when they are free to make the most of their talents and resources in open exchanges with other people who require their knowledge, service and expertise.</p>
<p>Immense possibilities for the Company’s economic growth have been unleashed by providing unprecedented, all encompassing financial solutions to the financially distressed through access to the multitude of financial solutions required in our complex economic times.</p>
<p><img src="http://stockguru.com/lt/GPAX/interiorshot.jpg" alt="" width="360" height="270" /></p>
<ul>
<li>In 2008, Halo experienced significant growth when sales grew to 252% of 2007’s numbers</li>
<li>Currently Halo has over 100 employees and independent contractors</li>
<li>Halo&#8217;s facilities include 34,618 square feet located in One Allen Center located on Central Expressway, a major thoroughfare in One Allen Center, Allen, Texas, which is 23 miles north of downtown Dallas</li>
<li>Website: http://www.myhalogroup.com/</li>
</ul>
<p>Nine of the 12 Halo companies have distinct core competencies and able to operate as stand-alone businesses.</p>
<table border="0">
<tbody>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/vert/debt_solutions.png" alt="" width="148" height="225" /><a href="http://stockguru.com/lt/GPAX/haloloanV.png"></a></td>
<td>Halo Debt Solutions, Inc. is an industry leader in debt settlement services, negotiating and settling various types of unsecured debts, saving clients thousands of dollars. Halo Debt revenue has significantly increased over the past year with top line revenues of $2.02M for the three months ended September 30, 2009.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/vert/group_mortgage.png" alt="" width="148" height="225" /><a href="http://stockguru.com/lt/GPAX/halocreditv.jpg"></a></td>
<td>Halo Group Mortgage, LLC continues to thrive in a down market due to its conservative lending approach and commitment to high quality loans. Now more than ever, there is an opportunity to rise up as a major player in the mortgage markets, supplemented by Halo&#8217;s full suite of related services.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/vert/group_realty.png" alt="" width="148" height="225" /><a href="http://stockguru.com/lt/GPAX/halodebtv.jpg"></a></td>
<td>Halo Group Realty, LLC will further Halo’s mission to provide a one-stop-shop of financial services and will allow for the opportunity to maximize profitability through increased synergy between its subsidiaries.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/vert/credit_solutions.png" alt="" width="148" height="225" /></td>
<td>Halo Credit Solutions, LLC disputes credit report inaccuracies and errors on behalf of a consumer, over a six-month time frame or less. The consumer exits the program with a guaranteed accurate credit report as verified by the credit reporting agencies.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/redo/halo_benefits.png" alt="" width="148" height="225" /></td>
<td>Halo Benefits, Inc. evolved to manage business relationships and strategic partnerships that positively affect several of the companies under the Halo umbrella. Key business-to-business marketing concepts and a centralized consumer-based call center were established to facilitate the marketing needs of the subsidiaries. Halo Benefits has implemented two programs that have the opportunity to quickly grow the customer base for each company within the Halo family. These efforts are WeCare and HaloCare.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/redo/halo-loan-modification-services.png" alt="" width="148" height="225" /></td>
<td>Halo Loan Modification Services, LLC has created an innovative and holistic approach to mortgage default resolution that is unparalleled in the industry. This unique strategy will put borrowers into a systematic and streamlined work-out process establishing affordable, long-term mortgages while achieving an improved return for bankers and investors compared to foreclosure.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/redo/halo-loan-modification-services.png" alt="" width="148" height="225" /></td>
<td>Halo Select Insurance Services, LLC is a partner in Halo Choice Insurance Services, LLC, a company in which Halo Companies, Inc. owns a 49% interest. Halo’s extensive client database is expanding every day. The ability to offer a highly-utilized product such as Property and Casualty insurance at a cost savings will translate into a better financial position for Halo’s clients and produce another steady revenue stream for Halo.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/vert/financial_solutions.png" alt="" width="148" height="225" /></td>
<td>Halo Financial Services, LLC is a consumer debt education, analysis and workout program that utilizes cutting edge technology and algorithms to produce the best scenario determined for each individual. The Halo Smart technology is derived from thousands of case studies which were evaluated and logged with consideration based on multiple factors. Factors state, region, income level, debt load, type of debt, and many others.</td>
</tr>
<tr>
<td><img src="http://www.stockguru.com/l/gpax/redo/halo-portfolio-advisers.png" alt="" width="148" height="225" /></td>
<td>Halo Portfolio Advisors, LLC leverages the complete Halo business-to-consumer suite of services to market turnkey solutions to lenders. The company’s operational support services allow endless opportunities for strategic B2B relationships with major debt servicers.</td>
</tr>
</tbody>
</table>
<h2><strong>B2B and B2C Divisions</strong></h2>
<ul>
<li>Business-to-Consumer (B2C) Services are provided through group contractual agreements and on an individual basis to consumers</li>
<li>Business-to-Business (B2B) Services are provided under portfolio management, employer benefits and financial education</li>
</ul>
<p>Many debt servicers are currently overwhelmed with imposed programs that require more resources&#8211;such as people, money, and time&#8211;than are necessary to be effective. The driving force behind a typical distressed asset is often not a single factor, but rather several contributing factors. When a loan is underperforming, it may be due to other outside influences of financial stress, such as a high unsecured debt load held by the consumer. Halo Portfolio Advisors’ operational support services allow endless opportunities for strategic B2B relationships with major debt servicers.</p>
<p>Hedge funds and other entities have recently purchased huge lots of mortgage portfolios. Halo is ready to step up to the plate and address the fundamental issues to service these mortgages.</p>
<p>Halo Benefits, Inc. sells Halo’s services as a bundled package through business relationships and strategic partnerships.</p>
<p>Halo facilitates the acquisition of additional companies and provides capital and expertise to increase the volume and profitability of each subsidiary.</p>
<h2><span style="font-size: large;">Halo Companies’ Business Model</span></h2>
<p>The Company’s stunning rise has eclipsed the more traditional one prong financial solution companies by creating The Financial Service Company of the Future. This unprecedented business model – of a one stop shop for financial services &#8212; has come of age – providing the ultimate business model in a time of countless job losses, home losses, the decimation of retirement accounts and untold family upheavals.</p>
<p>Halo has married the brightest minds in technology with those of finance in a collaboration which has produced a company setting a new standard in the industry.</p>
<p>Halo&#8217;s positive financial implications of Halo&#8217;s one step at a time, custom tailored financial solutions which delivers dynamic business results for clients in a multitude of fiscal areas creates lasting shareholder value. Halo Companies provides the middleclass a chance, an opportunity to regain their life and their lifeline while building a dynamic company with subsidiaries capable of enhancing mutual growth.</p>
<h2>Financial Difficulties Multi-lateral and Complex for Clients</h2>
<p>The industry as a whole typically does a poor job of addressing the total debt load of a borrower. Most models used to qualify a borrower for a loan modification use crude estimates of the borrower&#8217;s debt load. Buying behavior and future suitability and accountability are not fully developed or tracked. The servicer is solely focused on the overwhelming number of defaults before it, and concentrates only on the loan it services.</p>
<p>Halo Companies addresses the fact that financial difficulties are not singular. Most clients will have several issues which are interrelated.</p>
<p>In historic American fashion and proportion – out of the chaos, in the truest capitalistic fashion – a solution is born in a time of the most devastating recession since the Great Depression.</p>
<p>Halo Companies, Inc. recognized the difficulties and provided a solution. The middle class is in free fall and there is no one coming to their rescue.</p>
<ul>
<li>One in seven households with mortgages was either in foreclosure or delinquent on payments at the end of September 2009, according to the most recent data available from the Mortgage Bankers Association</li>
<li>Some owners are defaulting because they have lost their jobs. Some are giving up their homes because the value has fallen below what they owe</li>
<li>Prices have fallen 29% from their July 2006 peak to October 2009, based on the S&amp;P/Case-Shiller Home Price Index, which tracks home values in 20 cities</li>
<li>Nearly one in four mortgage holders owe more than their homes are worth, according to First American CoreLogic</li>
<li>Potential buyers of new homes are trapped in homes they are unable to sell</li>
<li>Nearly 6.2% of mortgages in Arizona, 9.4% of mortgages in Nevada, 5.8% in California were in foreclosure according to the Mortgage Bankers Association. 37,000 Connecticut mortgages or one in every 14, were in foreclosure or 90 days past due, with unemployment at 8.2 percent</li>
<li>National rates indicate one in 11 mortgages in foreclosure or 90 days late</li>
<li>National jobless rate stands firmly at 10 percent</li>
<li>Clients have ongoing debts accumulating after losing their jobs</li>
</ul>
<p>Halo’s approach indicates a full understanding of the fundamental reality of distressed middle America. Many have reduced incomes, homes worth more than what is owed and overwhelming credit card debt.</p>
<h2>Obtain the Best People</h2>
<p>The perfect marriage of financial experience and in-depth understanding of the all encompassing lapse of our financial system has produced Halo Companies. Halo does more than understand; it translates complex financial issues with their knowledge and technology into customized solutions for their clients&#8217; specific needs.</p>
<p>Scalable technology has served to provide a one stop shop solution for a target demographic of middle-class Americans who have been the victims of this country’s financial chaos.</p>
<p>Halo understands the effect hiring the right employees, surrounding them with great managers, and engaging them in their work.</p>
<h2>Officers and Directors</h2>
<p><img src="http://stockguru.com/lt/GPAX/cade.jpg" alt="" /><br />
<strong> Cade Thompson, Chairman/CEO/Director</strong><br />
A Co-Founder of Halo Companies, Inc., Cade Thompson has a proven record in multiple financial services industries. Graduating from Abilene Christian University studying Finance, Accounting, and History, Thompson gained further insight and experience while studying abroad as a Presidential Scholar at Oxford University.</p>
<p>After earning his Series 7, Series 63, and Life &amp; Health Licenses, he helped build a prospering financial advising agency under the umbrella of the broker dealer, World Group Securities. During the refinance surge at the turn of the decade, he expanded his experience by joining and eventually owning Halo Group Mortgage. Since then, Thompson has been instrumental in the developmental growth of Halo and its subsidiaries.</p>
<p><img src="http://stockguru.com/lt/GPAX/paul.jpg" alt="" /><br />
<strong> Paul Williams, Vice Chairman/CFO/Director</strong><br />
Paul Williams has over 30 years of business experience primarily in the capital markets and mergers &amp; acquisitions. Williams has served as the Chairman or CEO of numerous companies operating in various industries, both domestic and international, including one other publicly-traded company. He has helped open company offices in China, Russia and Latin America. Williams is also heavily involved in local, state and national civic affairs. He was appointed to three terms on the Board of the Texas Economic Development Council in Austin.</p>
<p>In 2009, Williams was awarded the CFO of the Year Award by the Dallas Business Journal for companies under $50 million in revenue. In 2007, Williams served as the Chairman of the Board for the Frisco Chamber of Commerce. He still serves on the Board today, and has also served on the boards of three other local and regional chambers in years past. He recently served two years on the advisory board of a local bank. Williams graduated from Austin College in Sherman with a double-major in Economics and Business Administration. He also graduated from the Institute of Organization Management.</p>
<p><strong><img src="http://stockguru.com/lt/GPAX/tony.jpg" alt="" /><br />
Tony Chron, President/Director</strong></p>
<p>Tony Chron joined Halo Companies, Inc. in September 2009 to serve as President, bringing with him more than thirty-three years of experience in both public and private companies. Prior to joining Halo Companies, Inc., Chron was a Senior Partner with Trademark Property Company, a major mixed-use and retail developer and served in various executive capacities including, most recently, as Executive Vice President. Chron also served as Associate Corporate Counsel and Director of Real Estate and Property Management for Pier 1 Imports, Inc., General Counsel and Vice President of Real Estate for Sunbelt Nursery Group, Inc., and Vice President of Real Estate and Real Estate Legal for Michaels Stores, Inc.</p>
<p>Chron has been a licensed attorney in the State of Texas for more than twenty-six years. Chron graduated with his Juris Doctor degree from South Texas School of Law in 1983. He also has a Bachelor of Science degree from Abilene Christian University.</p>
<p><img src="http://stockguru.com/lt/GPAX/jimmy.jpg" alt="" /><br />
<strong> Jimmy Mauldin, Chief Strategy Officer/Director</strong></p>
<p>A Co-Founder of Halo Companies, Inc., Jimmy Mauldin has broad strategic experience, primarily in sales and marketing. Mauldin has a proven track record, setting a national sales record with Henco, Inc., serving as Vice President of Sales for Associated Publishing, Co., and developing multiple start-up companies, including several e-commerce programs.</p>
<p>Mauldin served as Founder and Chief Executive Officer of Fund America Now, a national fund-raising company, and also established and serves as a director for the Halo Institute for Financial Education, a 501(c)(3) corporation.</p>
<p><img src="http://stockguru.com/lt/GPAX/scott.jpg" alt="" /><br />
<strong> Scott McGuane, Chief Marketing &amp; Sales Officer</strong></p>
<p>Scott McGuane joined Halo Companies, Inc, in January 2009, bringing with him more than twenty years of experience in financial services, retail lending and residential mortgage with companies such as Accredited Home Lenders, Inc., Bear Stearns, Citigroup, and AIG. Before that, McGuane provided consulting for strategic planning, mergers and acquisitions process reengineering and change management across a wide range of industries, including start-up ventures, non-profits, banking, telecommunications, energy and public utilities.</p>
<p>He has successfully managed product pricing and positioning, lead system development, licensing, operational responsibilities, and marketing efforts such as branding, point-of-sale, branch offices, online, direct mail, and telemarketing. McGuane received his Master of Business Administration at Southern Methodist University in Dallas, Texas and received a Bachelor of Science from Central Washington University in Ellensburg, Washington.</p>
<p><img src="http://stockguru.com/lt/GPAX/craig.jpg" alt="" /><br />
<strong> T. Craig Friesland, Chief Legal Officer/Director</strong></p>
<p>T. Craig Friesland is a Co-Founder of Halo Companies, Inc. Additionally, Friesland practices law in his own firm. Previously, he practiced with one of the largest law firms in Texas for over six years. Friesland was admitted to the State Bar of Texas in 1998 and serves as a member of the Real Estate, Probate, and Trust Law Section, and the Taxation Section of the State Bar of Texas. He is also a member of the Probate, Trusts, and Estates Section, and the Tax Section of the Dallas Bar Association.</p>
<p>Friesland graduated with his Juris Doctor degree from Baylor University School of Law in 1998. He also has a Master of Business Administration degree from Baylor University and a Bachelor of Business Administration degree in Finance from The University of Texas at Austin.<br />
<img src="http://stockguru.com/lt/GPAX/richard.jpg" alt="" /><br />
<strong> Richard Morris, Director</strong></p>
<p>Richard G. Morris, a Co-founder of Halo Companies, has served as a Director since its inception in January 2007. Prior to joining Halo Companies, he served in various positions with United Parcel Service from 1976 until March 2002, most recently, from January 2001 to March 2002 as one of its three District Operations Managers. In that role, Mr. Morris was responsible for 5,400 employees, a staff of 18 senior managers, a monthly operating budget of approximately $28 million, and revenues in excess of $35 million. After departing UPS in July 2002, Mr. Morris became the principal owner of Rammco Distributors, Incorporated, an equipment rental company which he still owns.</p>
<p>In July 2004, Mr. Morris co-founded Blue River Development, Inc., a real estate investment and development company, and is currently the sole owner and operator of this company. In August 2008, Mr. Morris acquired Port City, Inc., a plastics manufacturing company which Mr. Morris also currently owns and operates.</p>
<h2>Manage Growth</h2>
<p>Halo Companies has carefully focused its growth on sustainable and productive relationships. Extensive research and development frame Halo’s consulting model, which is built on an algorithmic foundation that creates sustainable client relationships and authentic growth.</p>
<p>Halo works to identify those clients will benefit most from its solutions and return the clients to a solid financial base. Halo’s refined technological strategies deliver results that have a profound impact on the lives of its clients and in return Halo’s bottom line.</p>
<h2>Halo Companies’ Subsidiaries</h2>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-debt-solutions.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Debt Solutions, Inc.<br />
www.halodebt.com</strong></p>
<p>Opportunity: The latest statistics from the Federal Reserve indicate that the total amount of consumer debt outstanding in the United States stands at roughly $2.5 trillion dollars. Based on the latest Census statistics, that works out to be nearly $8,100 in debt for every man, woman and child in America.</p>
<p>Capitalizing on the Opportunity: Halo Debt Solutions, Inc. (“Halo Debt”) is an industry leader in debt settlement services, negotiating and settling various types of unsecured debts, saving clients thousands of dollars.</p>
<p>Results: Halo Debt revenue has significantly increased over the past year top line revenues of $2.02MM for the three months ended September 30, 2009, Halo Debt reported $2.37MM for the three months ended June 30, 2009, and $2.15MM for the three months ended March 31, 2009 as compared to top line revenues of $1.04MM for the three months ended September 30, 2008, $863K for the three months ended June 30, 2008, and $654k for the three months ended March 31, 2008.</p>
<p>Competitive Advantage: Within Halo Debt, a team of industry experts has built and continually maintains a cooperative relationship with creditors to provide the best possible results for each client&#8217;s debt situation. To avoid ineffective and costly efforts of an outside collection company, creditors work cooperatively with companies like Halo Debt to reduce a client&#8217;s debt balances.</p>
<p>Model: The primary goal is to help clients achieve a debt-free lifestyle. Halo Debt’s programs are developed with affordable payment plans, based upon the client&#8217;s personal financial situation. The majority of the payment plans are designed to eliminate each client&#8217;s debt in 12 to 48 months. The average negotiated settlement offer is $0.43 (forty-three) cents on the dollar.</p>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-group-morgage.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Group Mortgage, LLC<br />
www.halogm.com</strong></p>
<p>Opportunity: Over the last year, the world has watched the American mortgage industry teeter on the brink of collapse. Thousands of mortgage company employees have lost their jobs while hundreds of thousands of Americans have lost their homes due to the millions of non-performing loans that were originated in past years.</p>
<p>Capitalizing on the Opportunity: Halo Group Mortgage, LLC (“Halo Group Mortgage”) has not only survived this crisis, but continues to thrive in a down market due to its conservative lending appetite and commitment to high quality loans. Now more than ever, there is an opportunity to rise up as a major player in the mortgage markets.</p>
<p>Results: Halo Group Mortgage recognizes the impact that home ownership has in strengthening both families and communities, while providing fuel for economic growth for our country. By providing the best loan products for its customers, Halo Group Mortgage hopes to increase the opportunities for home ownership within local communities and across the nation.</p>
<p>Competitive Advantage: Halo Group Mortgage has the resources to assist consumers in achieving their financing goals, unlike any other mortgage broker in the marketplace.</p>
<p>Model: Halo Group Mortgage is a full service, Texas-based, mortgage brokerage institution in the retail lending environment, serving strategic U.S. markets for “A” paper residential mortgage loans. Currently licensed in four states, Halo Group Mortgage specializes in partnering America’s top banks with both current and potential homeowners for the closing of real estate mortgage transactions. Halo Group Mortgage can earn up to 5% of the loan amount for providing this service.</p>
<p><img src="http://www.stockguru.com/l/gpax/group-realty.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Group Realty, LLC<br />
www.halogr.com</strong></p>
<p>Opportunity: The addition of Halo Group Realty, LLC (“Halo Group Realty”) will further Halo’s mission to provide a one-stop-shop of financial services and will allow for the opportunity to maximize profitability through increased synergy between our subsidiaries.</p>
<p>Capitalizing on the Opportunity: Halo estimates that over two-thirds of the customers in the credit repair process are motivated to purchase a new home. Many debt settlement customers are also motivated to own a home in the near future. In addition, many of our mortgage clients begin their process with a pre-approval before choosing a home. Halo Group Realty is a logical progression for a Halo client, regardless of the client’s starting point.</p>
<p>Results: Halo Group Realty will capitalize on the internal lead development of the other Halo entities and as a byproduct will materialize the final step in the home ownership process. This will add additional revenue and increase brand awareness by having Halo signage in yards across the country.</p>
<p>Competitive Advantage: Halo Group Realty has the ability to serve a larger segment of potential homebuyers by leveraging the tools offered by Halo. In contrast, a competing realtor will narrowly focus on the homebuyer who will make an immediate purchase decision. Halo Group Realty will therefore have contact with its customers for a longer amount of time, will generate a larger pipeline of business for its realtors, and ultimately provide more tangible benefits to our customers than are available from Halo&#8217;s competitors.</p>
<p>Model: Halo Group Realty’s listings will be charged at 6%. When serving buyers, Halo Group Realty will generate revenue from 3% commissions and any bonuses available for the sale. In addition, Halo Group Realty will earn commissions from referrals to apartment complexes, and build a pipeline of business for Halo Credit and Halo Group Mortgage.</p>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-credit-solutions.png" alt="" width="335" height="109" /><br />
<strong> Halo Credit Solutions, LLC<br />
www.halocredit.com</strong></p>
<p>Opportunity: The U.S. Public Interest Research Companies (PIRG) has established that 79% of all credit reports in the U.S. contain errors that affect the credit score, 30% listed closed accounts as still open, and 25% contain errors serious enough to prevent the consumer from obtaining a loan.</p>
<p>Capitalizing on the Opportunity: Halo Credit Solutions, LLC (“Halo Credit”) disputes inaccuracies and errors on behalf of a consumer, over a six-month time frame or less. The consumer exits the program with a guaranteed accurate credit report as verified by the credit reporting agencies.</p>
<p>Results: Halo Credit has found that by correcting inaccurate information, the average customer’s FICO score increases by 56 points. A graduate of Halo Credit is more likely to be approved for financing, qualify for better interest rates, and be deemed “credit worthy.”</p>
<p>Competitive Advantage: Halo Credit uses proprietary credit repair management software to effectively manage thousands of credit disputes. A single credit processor can accurately maintain the dispute process for hundreds of clients at a time. In comparison, a processor could previously manage only a handful of customer disputes per month. As a result, each dispute is handled in the same manner time after time, assuring quality results. And due to the time savings, each customer receives personal attention on his or her account from a trained Halo Credit consultant.</p>
<p>Model: The cost of credit restoration is $199. Credit repair is both an integral part of the overall financial solutions that Halo Credit provides and a critical lead generating product utilized to capture increased national exposure for all the other subsidiaries. With its efficiency, Halo Credit maintains a healthy profit margin on each new client. Fixed costs are covered with a minimal amount of new customers per month. Due to Halo Credit’s efficiency, as customer acquisitions increase the variable costs of scaling up decrease on a percentage basis.</p>
<p>WeCare:<br />
WeCare partners with homebuilders in order to increase the credit worthiness of potential homebuyers through Halo’s services. When a potential homebuyer cannot qualify for a home loan, the client is referred to Halo to settle outstanding debt or restore credit. At the end of Halo’s work, the potential homebuyer is then referred back to the homebuilder through Halo Group Mortgage.</p>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-halo-benefits.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Benefits, Inc.</strong></p>
<p>Opportunity: As of mid-2007, each Halo subsidiary exclusively used direct-to-consumer marketing channels, but was lacking in any type of business-to-business channel. Additionally, each subsidiary individually managed its own consumer marketing efforts with no centralized strategy.</p>
<p>Capitalizing on the Opportunity: Halo Benefits, Inc. (“Halo Benefits”) evolved to manage business relationships and strategic partnerships that positively affect all of the companies under the Halo umbrella. Several key business-to-business marketing concepts and a centralized consumer-based call center were established to facilitate the marketing needs of each subsidiary.</p>
<p>Results: Halo Benefits has implemented two programs that have the opportunity to quickly grow the customer base for each company within the Halo family. These efforts are WeCare and HaloCare.</p>
<p>Model: Halo Benefits has created business partnership opportunities such as the following:</p>
<p>WeCare:<br />
www.wecareonline.org</p>
<p>WeCare partners with homebuilders in order to increase the credit worthiness of potential homebuyers through Halo’s services. When a potential homebuyer cannot qualify for a home loan, the client is referred to Halo to settle outstanding debt or restore credit. At the end of Halo’s work, the potential homebuyer is then referred back to the homebuilder through Halo Group Mortgage or Halo Group Realty.</p>
<p>HaloCare:</p>
<p>HaloCare offers financial solutions through Benefit Groups, Employee Assistance Programs and insurance programs on a per-member per-month (PMPM) basis. The association or group pays Halo a fee for their members to have access to Halo’s financial solutions, creating an additional source of revenue. In return, Halo’s services are offered to group members at a slightly reduced cost.</p>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-loan-modification-services.png" alt="" width="335" height="104" /><br />
<strong> Halo Loan Modification Services, LLC<br />
www.haloloanmod.com</strong></p>
<p>Opportunity: The latest statistics from the Federal Deposit Insurance Corporation indicate that 6.4 million loans are currently past due or are projected to become delinquent by mid-2010. Recidivism rates are reaching all-time highs at close to 50% for most servicers across the nation which, coupled with overwhelming consumer response, are leaving servicers unable to respond in a timely and efficient manner.</p>
<p>Capitalizing on the Opportunity: Halo Loan Modification Services, LLC has created an innovative and holistic approach to mortgage default resolution that is unparalleled in the industry.</p>
<p>Results: This unique strategy will put borrowers into a systematic and streamlined work-out process establishing affordable, long-term mortgages while achieving an improved return for bankers and investors compared to foreclosure. This type of approach can help stabilize the U.S. financial markets by minimizing foreclosures.</p>
<p>Competitive Advantage: To truly improve and resolve the re-default rates of the consumer due to poor financial decisions and obligations, Halo has developed an ongoing strategy to assist the consumer with unsecured debt burden, credit challenges, and general financial education. This multi-tiered approach will further improve the future performance of the modified loan and provide a fundamental shift in the methods and models previously used and that perpetuated the ever growing mortgage meltdown.</p>
<p>Model: Halo’s loan modification approach adopts the streamlined effectiveness of government sponsored loan modification programs and provides both the borrower and investor complete transparency into the decision making process. The result is consistent and predictable improvement to investors, reduced costs to both servicers and borrowers, and a thoroughly integrated approach to restoring financial integrity.</p>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-choice-inusrance-services.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Choice Insurance Services, LLC<br />
www.halochoice.com</strong></p>
<p>Opportunity: Halo’s extensive client database is expanding every day. As the number of financially-distressed individuals seeking Halo’s assistance increases, so does Halo’s warm market. The ability to offer a highly-utilized product such as Property and Casualty insurance at a cost savings will translate into a better financial position for Halo’s clients and produce another steady revenue stream for Halo.</p>
<p>Capitalizing on the Opportunity: Many of the clients presently utilizing Halo’s Debt Settlement, Credit Repair, Loan Modification, Mortgage and Real Estate companies may be currently overpaying for insurance services. Halo offers its clients competitively-priced insurance products that will save them money by providing a cost savings on monthly insurance premiums already allocated in their monthly budgets. This reduction in premium expense will free up cash flow for financially distressed clients, allowing them to settle their outstanding debt obligations much faster or accumulate and save additional funds for greater long term financial security.</p>
<p>Results: Halo will give clients a better all-around financial position through which to navigate these uncertain economic times. Halo’s current expectation is to attract and engage clients currently utilizing other Halo products, to use Halo’s insurance products – not just at the point of sale – but as ongoing conversions throughout Halo’s various product lifecycles.</p>
<p>Competitive Advantage: By adding a broad spectrum of insurance products to its current product offerings, Halo can now position itself before tens of thousands of clients – clients who are already enrolled in products and services offered by other Halo subsidiaries – and who would welcome a value-added product offering from the company they already know and trust.</p>
<p>Model: Halo Select Insurance Services, LLC is a partner in Halo Choice Insurance Services, LLC, which is currently licensed in Texas, New Mexico, Oklahoma, and Mississippi and represents the lines of hundreds of insurance companies, including Safeco, Travelers, CNA, Progressive, and The Hartford. Halo is therefore not limited to the product and service offerings of a single insurance underwriter, allowing Halo the ability to identify the lowest cost alternative for clients. Specifically, Halo offers Auto, Home, Life, Health and various other insurance products to meet the needs of its clients.</p>
<p><img src="http://www.stockguru.com/lt/GPAX/financialservices.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Finanancial Services, LLC</strong></p>
<p>Opportunity: A traditional debt relief program is increasingly limited in the number of states in which it can operate. Halo Financial Services has developed a model that will allow it to operate in 47 states. That is 26 more states in which Halo can now offer debt relief services to consumers. Additionally, a wide gap exists in the marketplace for a debt relief company that provides education and in-depth analysis specific to the consumer’s profile before recommending a solution for that consumer.</p>
<p>Capitalizing on the Opportunity: Few if any debt relief companies have the resources to perform the analysis Halo Financial Services offers. The company provides education &amp; analysis based on a proprietary algorithm that takes into account multiple factors within a consumer’s financial portfolio and history and then weighs them according to their significance to the consumer’s specific situation. Factors include consumer risk tolerance, discretionary income, propensity to repay, debt load, type of debt, state, and region.</p>
<p>Results: Providing services tailored to each consumer increases client satisfaction and therefore increases client retention. Because the consumer is recommended for enrollment based on the unique analysis, the overall rate of program success continues to increase. Clients that do not qualify for the programs provided directly by Halo can still be monetized by Halo through relationships with bankruptcy networks and debt management and credit counseling companies.</p>
<p>Competitive Advantage: Halo’s unique ability to provide multiple solutions under one roof offers more value to the consumer. In addition, Halo’s technology allows the company to manage a higher volume of consumers with an increased efficiency of resources that incorporates the predictability of results.</p>
<p>Model: The primary goal is to help consumers find the right program for their financial profile allowing for the highest degree of success. Halo Financial Services is designed with a minimal upfront fee, very small monthly service charge, and a success fee only after the accounts have been settled and satisfied.</p>
<p><img src="http://www.stockguru.com/l/gpax/redo/horizontal-portfolio-advisors.png" alt="" width="335" height="109" /></p>
<p><strong>Halo Portfolio Advisors, LLC</strong></p>
<p>Opportunity: In today’s economy, lenders are experiencing an overflow of distressed assets. Many debt servicers are currently overwhelmed with imposed programs that require more resources&#8211;such as people, money, and time&#8211;than are necessary to be effective.</p>
<p>Capitalizing on the Opportunity: The driving force behind a typical distressed asset is often not a single factor, but rather several contributing factors. When a loan is underperforming, it may be due to other outside influences of financial stress, such as a high unsecured debt load held by the consumer. Halo Portfolio Advisors’ operational support services allow endless opportunities for strategic B2B relationships with major debt servicers.</p>
<p>Results: Halo Portfolio Advisors’ servicing capacity allows for the management of a diverse portfolio of loans. Halo’s technology systems are bundled with transparency, accountability, efficiency, speed, and flexibility. This unique strategy deposits borrowers into an intelligent, results-driven process that establishes affordable, long-term mortgages while also achieving an improved return for lenders and investors, when compared to foreclosure.</p>
<p>Competitive Advantage: Halo’s approach can help stabilize the U.S. financial markets by minimizing foreclosures on the 6.4 million loans that are currently past due or are projected to become delinquent by mid-2010. Halo’s technology can provide deeper insight into the complete financial picture of a borrower &#8211; an insight that is unprecedented in the industry today.</p>
<p>Model: Halo Portfolio Advisors leverages the complete Halo business-to-consumer suite of services to market turnkey solutions to lenders.</p>
<h2>Halo Companies Inc. National and Regional Recognition</h2>
<p>Halo has been recently recognized by Inc. Magazine, Capital One Bank, Comerica Bank&#8217;s, and the SMU Cox School of Business.</p>
<p>Halo Companies, Inc. Honored with Celebration of Enterprise Award</p>
<p>November 05, 2009 &#8211; Honored by Capital One Bank recently when it received the Celebration of Enterprise Award. The Celebration of Enterprise Award is designed to recognize entrepreneurial spirit and reward those who saw significant economic growth and overcame daunting obstacles to achieve that growth. Halo Companies, Inc. was selected from a group of seven finalists as the winner of their category.</p>
<p>Dallas CFO of the Year Award</p>
<p>October 27, 2009 &#8211; Chief Financial Officer Paul Williams honored as the recipient of the Dallas CFO of the Year Award. The award is judged and presented as a part of the Dallas Business Journal&#8217;s annual awards program. Under Williams&#8217; financial leadership during the last year, Halo has seen impressive growth and increased shareholder value at a rate of 252%.</p>
<p>Paul Williams has over 30 years of business experience primarily in the capital markets and mergers &amp; acquisitions. The CFO of the Year finalists were selected for being among the most outstanding CFOs in North Texas. Candidates were considered for their contributions to their company&#8217;s growth and/or profitability, areas of corporate management in addition to the CFO role, as well as contributions to the community outside the company. Finalists and winners were selected by an independent judging panel consisting of past winners and recommended judges from ACG, the Dallas CPA Society, and FEI.</p>
<p>President Mortgage Orb Person of the Week</p>
<p>August 28, 2009 &#8211; Scott McGuane, president of Halo Companies, Inc., was recognized by mortgageorb.com as Person of the Week. The recognition includes a feature of Mr. McGuane on mortgageorb.com where he answers questions about the challenges facing the mortgage industry and provides insight to forward-looking solutions that Halo Companies, Inc. actively seeks to provide.</p>
<p>Scott McGuane joined Halo Companies, Inc. in January to serve as president. Mr. McGuane has more than twenty years&#8217; experience in financial services, retail lending and residential mortgage with companies such as Accredited Home Lenders, Inc., Bear Stearns, Citigroup, and AIG. Before that, McGuane provided consulting for strategic planning, mergers and acquisitions process reengineering and change management across a wide range of industries.</p>
<p>Inc. Magazine Recognizes Halo as One of the Fastest Growing Companies in America</p>
<p>August 18, 2009 – Halo Group, Inc., a subsidiary of Halo Companies, Inc., was recognized by Inc. Magazine this month in the 28th annual issue ranking the fastest growing private companies in America. Halo was recognized as the 533rd fastest growing company in America.</p>
<p>Inc. Magazine publishes a comprehensive listing of the fastest growing companies in America each year. The list is composed of companies that range across industries from construction and manufacturing to financial services. Halo Group, Inc. was recognized as number 16 in the region and 23 in the financial services industry. The list can be viewed in its entirety online at www.inc.com.</p>
<p>Inc. Magazine, delivers advice, tools, and services, to help business owners and CEOs start, run, and grow their businesses more successfully. You’ll find information and advice covering virtually every business and management task, including marketing, sales, finding capital, managing people, and much, much more. Visit www.Inc.com for more information.</p>
<p>Comerica Bank Recognition as Third Fastest Growing Company in Region</p>
<p>June 23, 2009 – Honored by Comerica Bank by earning the third spot in the annual Collin 60. The Comerica Bank Collin 60 showcases the FASTEST growing companies in one of the fastest growing counties in the country. Collin County is one of the fastest growing counties in America, and 15,000 companies call Collin County home, making this a significant achievement to be recognized as the 3rd fastest growing company in this community.</p>
<p>The Comerica Bank Collin 60 has been established to show the world the strength of business in this dynamic growth area of the country. The cities of Allen, Celina, Far North Dallas, Farmersville, Frisco, McKinney, Melissa, Murphy, Plano, Prosper, Richardson and Wylie and many others are included in the search.</p>
<p><strong>Halo Companies, Inc.<br />
One Allen Center<br />
Suite 500<br />
700 Central Expressway South<br />
Allen, TX 75013<br />
Phone: 214-644-0065</strong></p>
<p><a href="http://haloco.com"><strong>http://haloco.com</strong></a></p>
<p>Cautionary Language Concerning Forward-Looking Statements:</p>
<p>Information set forth in this profile contains financial estimates and other forward-looking statements that are subject to risks and uncertainties, and actual results might differ materially. A discussion of factors that may affect future results is contained in Halo Companies Inc.&#8217;s filings with the Securities and Exchange Commission. Halo Companies, Inc. disclaims any obligation to update and revise statements contained in this profile based on new information or otherwise.</p>
<p>Disclosure</p>
<p>Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was paid thirteen thousand dollars by the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Halo Companies, Inc. (OTCBB: HALN) during the promotional period.</p>
<p><strong> </strong></p>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/03/haln-overview/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Location Based Technologies, Inc.</title>
		<link>http://www.shareholdervision.com/2010/02/location-based-technologies-inc/</link>
		<comments>http://www.shareholdervision.com/2010/02/location-based-technologies-inc/#comments</comments>
		<pubDate>Tue, 16 Feb 2010 12:25:50 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/wp/?p=44</guid>
		<description><![CDATA[Location Based Technologies based in Anaheim, Calif., is a leading edge developer and provider of personal locator devices and services utilizing patented, proprietary technologies to enhance and enrich the lives of families globally.]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/44.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<h2>Location Based Technologies, Inc.</h2>
<p>OTCBB: LBAS</p>
<p>4989 E. La Palma Ave.<br />
Anaheim, CA 92807</p>
<p>Phone: (800) 615-0869<br />
Fax: (714) 200-0287</p>
<p>Websites</p>
<p>Corporate &#8211; <a href="http://www.LocationBasedTech.com/">www.LocationBasedTech.com</a><br />
Pocketfinder &#8211; <a href="http://www.PocketFinder.com/">www.PocketFinder.com</a><br />
Investor Relations: <a href="http://www.RedwoodConsultants.com/">www.RedwoodConsultants.com</a></p>
<h2>Company Profile:</h2>
<p>Location Based Technologies (OTCBB: LBAS)  based in Anaheim, Calif., is a leading edge developer and provider of personal locator devices and services utilizing patented, proprietary technologies to enhance and enrich the lives of families globally.</p>
<p>The company is located in Orange County, California and its mission statement is “Linking People through Technology”.  The company utilizes existing  and emerging technology to safeguard people, pets, or possessions, and to help families stay connected.</p>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/device-in-charger.jpg"><img class="alignright size-full wp-image-50" title="device-in-charger" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/device-in-charger.jpg" alt="" width="265" height="267" /></a>Location Based Technologies (OTCBB: LBAS)  uses internal research to develop a wide variety of innovative technologies with the primary goal of integration with its GPS based retail products and services.  The company’s focus on internal research gives it the ability to quickly innovate and improve products, and give it a technological advantage in the location based industry.  LBAS makes its expertise available to direct partners through a technology licensing program, a winning situation for all parties</p>
<p>LBAS is in the business of providing products and services that provide “peace of mind” and security in knowing that people, animals, and valuables are safe.  The company provides both switch and network-based products that utilize wireless data services, voice recognition, and location-based tracking services.  The company hosts computer application software to search and retrieve data from databases and computer networks on a monthly basis for subscribers.</p>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/pocket-logo.gif"><img class="aligncenter size-full wp-image-51" title="pocket-logo" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/pocket-logo.gif" alt="" width="500" height="107" /></a>The primary product LBAS is know for is Pocketfinder. The device, shown above in its charging unit, is very small and can easily be concealed in a pocket or a purse. The device is great for keeping a safe watch on your kids or a family member who might get lost.</p>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/pet-logo.gif"><img class="aligncenter size-full wp-image-52" title="pet-logo" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/pet-logo.gif" alt="" width="266" height="80" /></a>Petfinder is the same device used for keeping your pet safe. It easly goes on a dog&#8217;s collar, and allows you to know that your dog is safe.</p>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/baggage.gif"><img class="aligncenter size-full wp-image-53" title="baggage" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/baggage.gif" alt="" width="500" height="217" /></a>Pocketfinder Luggage keeps a safe eye on your bag. If your flight makes it to New York and your bag makes it to New Zealand, you are going to know where to have the airline search.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/02/location-based-technologies-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medizone International Annual General Meeting</title>
		<link>http://www.shareholdervision.com/2010/02/medizone-international/</link>
		<comments>http://www.shareholdervision.com/2010/02/medizone-international/#comments</comments>
		<pubDate>Wed, 10 Feb 2010 23:04:18 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/wp/?p=68</guid>
		<description><![CDATA[Recorded by Shareholder Vision on August 26, 2009 at the Medizone International (OTCBB: MZEI) Annual General Meeting in Reno, Nevada.]]></description>
			<content:encoded><![CDATA[Recorded by Shareholder Vision on August 26, 2009 at the Medizone International (OTCBB: MZEI) Annual General Meeting in Reno, Nevada.]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/02/medizone-international/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>LD Holdings, Inc.</title>
		<link>http://www.shareholdervision.com/2010/02/ld-holdings-inc-2/</link>
		<comments>http://www.shareholdervision.com/2010/02/ld-holdings-inc-2/#comments</comments>
		<pubDate>Wed, 10 Feb 2010 22:59:46 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/wp/?p=64</guid>
		<description><![CDATA[LD Holdings, Inc. has adopted a business model that seeks to capitalize on the massive transfer of generational assets as the “Baby-Boomer” generation transitions from the ownership of small businesses into retirement. ]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/64.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<h2>LD Holdings, Inc.</h2>
<p>OTCBB: LDHL</p>
<p>1070 Commerce Drive, Building 2, Suite 303<br />
Perrysburg, OH 43551</p>
<p>Phone: 419-873-1111<br />
Fax: 419-873-1141</p>
<p>Website:</p>
<p><a href="http://www.LDHoldings.com/">www.LDHoldings.com</a><br />
<a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/ldlh-logo.gif"><img class="alignleft size-full wp-image-61" title="ldlh-logo" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/ldlh-logo.gif" alt="" width="159" height="111" /></a>LD Holdings, Inc., (Symbol LDHL), has adopted a business model that seeks to capitalize on the massive transfer of generational assets as the “Baby-Boomer” generation transitions from the ownership of small businesses into retirement. The Baby-Boomer generation is represented by individuals born between 1946 and 1964. There are currently about 80 million Boomers in this age group.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/02/ld-holdings-inc-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hague Corp. (HGUE) &#8211; Solterra Renewable Technologies, Inc.</title>
		<link>http://www.shareholdervision.com/2010/02/hague-corp-hgue-solterra-renewable-technologies-inc/</link>
		<comments>http://www.shareholdervision.com/2010/02/hague-corp-hgue-solterra-renewable-technologies-inc/#comments</comments>
		<pubDate>Wed, 10 Feb 2010 11:04:52 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/wp/?p=28</guid>
		<description><![CDATA[By setting the standard for solar technology with distinctly superior cost and capital efficiency, they strive to be the world's largest solar energy technology company.]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/28.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<h2>Hague Corp. (OTCBB: HGUE) &#8211; Solterra Renewable Technologies, Inc.</h2>
<p>OTCBB: HGUE</p>
<p>14220 East Cavedale Road<br />
Scottsdale, Arizona 85262</p>
<p>Phone: 954-384-1487</p>
<p>Website:</p>
<p><a href="http://www.solterrasolarcells.com/">www.solterrasolarcells.com</a></p>
<p>Email:</p>
<p><a href="mailto:info@solterrasolarcells.com">info@solterrasolarcells.com</a></p>
<h2>Company Profile:</h2>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/hgue-logo.jpg"><img class="aligncenter size-medium wp-image-29" title="hgue-logo" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/hgue-logo-300x113.jpg" alt="" width="300" height="113" /></a></p>
<h3>The Solterra Mission</h3>
<h4>Solar power is The Solterra Mission</h4>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/pic1.jpg"><img class="alignright size-full wp-image-30" title="pic1" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/pic1.jpg" alt="" width="190" height="119" /></a><br />
Their mission is to become the leading producer of third generation photovoltaic cells (solar cells) through the use of Quantum Dots.</p>
<p>By introducing their thin film quantum dot solar cells, they plan to establish a disruptive technology that will help accelerate the conversion from a fossil fuel dependent energy infrastructure to one based on renewable and carbon-neutral energy sources. The products of Solterra Renewable Technologies will be part of the solution to energy independence, greenhouse gas emissions and global warming.</p>
<h3>The Solterra Vision</h3>
<p>At Solterra Renewable Technologies, their technology will make it possible to deliver grid-parity solar electricity. By setting the standard for solar technology with distinctly superior cost and capital efficiency, they strive to be the world&#8217;s largest solar energy technology company.</p>
<h3>The Solterra Goal</h3>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/pic2.jpg"><img class="alignright size-full wp-image-39" title="pic2" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/pic2.jpg" alt="" width="190" height="119" /></a></p>
<p>Their goal at Solterra Renewable Technologies, Inc. is to uses our robust IP portfolio in third generation photovoltaic materials and solar cell processing technology to produce the lowest priced solar power available today.</p>
<p>Solterra Renewable Technologies, Inc. will produce high volume hybrid solar cells using revolutionary low cost Quantum Dot synthesis technology and a proprietary conjugated polymer technology that delivers unmatched efficiency and production economy.</p>
<p>Solterra&#8217;s process does NOT require costly silicon or slow, cumbersome vacuum processing or sputtering methods, thereby creating a new paradigm in the industry.</p>
<h2>The Market</h2>
<p>Solar power is already in an explosive growth mode, but here Solterra we are singularly positioned to lead the development of truly cost- effecicient and sustainable solar technology as the first company to introduce a new dimension of cost reduction by replacing silicon wafer based solar modules with a low cost Quantum Dot based solar cell module.</p>
<p>Solterra&#8217;s process does NOT require costly silicon rare earth minerals or slow, cumbersome vacuum processing or sputtering methods, thereby creating a new paradigm in the industry. Furthermore Solterra can produce its own high quality tetrapod quantum dots using a revolutionary patent pending process that results in cost savings up to 95% over the traditional quantum dot manufacturing process.</p>
<h3>Low Cost Solar Cells</h3>
<p>Using proprietary technology, Solterra Renewable Technologies, Inc. will utilize our robust IP portfolio in third generation photovoltaic materials and solar cell processing technology to produ ce the lowest priced solar power available today.</p>
<p>Solterra Renewable Technologies, Inc. will produce high volume hybrid solar cells using revolutionary low cost Quantum Dot synthesis technology and a proprietary conjugated polymer technology that can and will deliver unmatched efficiency and production economy.</p>
<h3>Technology Breakthrough: Low Cost, High Effiency Cells</h3>
<p>Quantum dots are &#8220;mega-molecules&#8221; of semiconducting materials that are smaller than living cells. Q.D.’s interact with light in unique ways to give off different-colored light or to create electrons and holes, due partly to their tiny size, partly to their shape and partly to the material from which they are made. Using proprietary technologies, Solterra Renewable Technologies, Inc. will manufacture very low cost solar cells utilizing Q.D. Technology…(less than half the price of competition). Proprietary Q.D.’s are a primary ingredient in Solterra Renewable Technologies, Inc.’s solar cells. &#8220;Our work knocks down a big barrier in developing quantum dot-based photovoltaics as an alternative to the conventional, more expensive, silicon-based solar cells,&#8221; said co-author and principal investigator Michael Wong, Assistant Professor of Chemical and Biomolecular Engineering at Rice University. Dr. Wong explained that the way towards cheaper more efficient solar cells is to manufacture them using Quantum Dots.</p>
<p>Quantum Dot technology is by far the most efficient method of producing solar electricity but until recently the high cost of producing Q.D.’s made their use in Solar Panels prohibitive. Solterra Renewable Technologies, Inc. has changed that with a new proprietary Quantum Dot production technology. This new technology reduced the cost of Q.D. production by more than 90%. This new Q.D. production technique, developed by Dr. Wong of Rice University has been acquired by Solterra Renewable Technologies, Inc.</p>
<p>By applying this proprietary low cost production technology to the manufacture of Q.D.’s and applying it to Solar Energy Cells, the cost of solar generated electricity is reduced to little more than grid price at today’s electricity price. Grid prices are expected to increase by more than 50% over the next five years. Based on the above: in five years, solar energy using the Solterra Quantum Dot Technology will be approximately half the cost of grid pricing&#8230;</p>
<h2>Sunny Economic Forecast</h2>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/sunny.jpg"><img class="aligncenter size-full wp-image-38" title="sunny" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/sunny.jpg" alt="" width="600" height="249" /></a><br />
The solar energy industry, which encompasses technology, research, manufacturing, training, and installation, has a direct impact on many facets of U.S. commerce. Since the 1970s, when the solar energy market was virtually nonexistent, the business of solar energy has seen 100-fold price decreases, which has led to the production of millions of watts per year and created a national market worth about $2 billion. The current U.S. solar industry employs some 20,000 men and women in high-value, high-tech jobs, representing about 300 companies, universities, and utilities (estimates based on Directory of the U.S. Photovoltaics Industry. 1996. Washington, DC: Solar Energy Industries Association [SEIA]). And by 2020, the industry is expected to grow toward a workforce of 150,000 (&#8220;Energy Alternatives and Jobs.&#8221; 2000. Renewable Energy World, 3(6):November/December, pp. 26-32). Jobs associated with the solar energy industry are in engineering, science, management, architecture, construction, planning, education, sales, skilled labor, finance, and design.</p>
<p>The solar industry continues to grow steadily as costs for solar systems decline in the expanding markets for renewable energy. Since the late 1990s, the market for solar energy has grown at an annual rate of 20%. The solar industry estimates that growth rates above 25% annually are possible, resulting in a $27 billion market by 2020. With technological innovations lowering costs and increased market growth leading to new jobs and export opportunities, solar energy can become a major high-tech growth industry that contributes significantly to our economic growth and improves our trade balance.</p>
<h3>Solterra Product Innovations</h3>
<p>Solterra will be producing and distributing a Thin Film Quantum Dot PV Solar Cell, which is differentiated from other traditional PV cells by a unique technology that can result in lower cost, higher efficiency, and broader spectral performance.</p>
<p>Solterra&#8217;s Quantum Dot Solar Cell can achieve a dramatically lower manufacturing cost per watt in part, because we can manufacture our own quantum dots using a patent pending, revolutionary process that results in the production of extremely desirable, high quality tetrapod quantum dots at a cost savings in excess of 95%. To our knowledge Solterra is the only solar cell manufacture to date that does not rely on outside suppliers for its primary ingredients. Their third generation quantum dot solar cells do not require custom made, expensive ,nor complex, processing equipment, and we do not use costly silicon or rare earth elements such as indium. Solterra instead will rely on low-cost screen printing and/or inkjet techniques applied to inexpensive substrates. Quantum Dot Solar Cells have extremely high potential efficiency, having demonstrated the production of multiple excitons from a single electron. This phenomonon is the key to exponential increases in conversion efficiency. Quantum dot solar cells also have the ability to harvest light energy in the infrared and ultraviolet spectra leading to better low light collection efficiency and the potential to continue harvesting energy even when little or no visible light is present.</p>
<p>Solterra&#8217;s Solar cells will come to market competitively priced with the opportunity to reduce prices even further as economies of scale come into effect. Additionally they believe their quantum dot manufacturing capability and print based cell manufacturing process will enable the rapid deployment of additional manufacturing sites across the globe.</p>
<h3>The Solterra Advantage</h3>
<p>Solterra will be producing and distributing a Thin Film Quantum Dot PV Solar Cell which is differentiated from other PV cells by a unique technology that results in lower cost, higher efficiency, and broader spectral performance. Solterra&#8217;s Quantum Dot Solar Cell achieves a dramatically lower manufacturing cost per watt because no vacuum equipment is required, no expensive silicon is required and low-cost screen printing and/or inkjet techniques are used on inexpensive substrates. Secondly, the Solterra Thin Film Quantum Dot Solar Cell has the potential to generate multiple excitons from each proton providing the potential for exponential improvements in conversion efficiency. Third, Solterra&#8217;s PV cell is not only more efficient in the early morning and late afternoon compared to crystalline silicon PV cells, but it also has the potential to harvest light energy in the infrared and ultraviolet spectra.</p>
<p>Solterra&#8217;s Solar cells will be competitively priced with the potential to reduce prices even further as economies of scale come into affect.  Two charts on below show the advantage in dollars and cents&#8230; and good sense!</p>
<h2><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/pick5.gif"><img class="aligncenter size-full wp-image-40" title="pick5" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/pick5.gif" alt="" width="448" height="591" /></a></h2>
<h2>The Solterra Leadership</h2>
<h3>Mannagement Team</h3>
<h4>Stephen Squires &#8211; President &amp; CEO</h4>
<p>Stephen is the Principal Inventor and Chief Technologist for Solterra Renewable Technologies, Inc., an advanced technologies innovation group. He has over 25 years experience in advanced materials and technologies. Prior to Solterra, Stephen was at McDonnell Aircraft developing and adapting advanced materials for combat aircraft applications. He was also CEO of Aviation Composite Technologies Inc., which he grew to have over 200 employees and $20 million in revenue. ACT was merged with USDR Aerospace in 2001. He has pursued his interest in advanced materials and more specifically Nano fibers and carbon Nanotubes, where he quickly recognized the potential of the unique quantum features these materials held.</p>
<h4>David Doderer &#8211; VP</h4>
<p>David has over 15 years of research and development experience in emerging technologies including biotechnology, nanotechnology and quantum physics. Most recently serving as principal investigator for USGN, he co-authored numerous patents/patents pending and proprietary processes, and managed Hudler Titan LLC, a technology consulting company.</p>
<h4>Ghassen E. Jabbour, PhD &#8211; CSO</h4>
<p>Director of Flexible and Organic Electronics Development at the Flexible Display Center (FDC) and a Professor of Chemical and Materials Engineering at Arizona State University. Professor Jabbour is also the Technical Advisory Board Leader on Optoelectronic Materials, Devices and Encapsulation at FDC. He has been selected to the Asahi Shimbun 100 New Leaders of the USA and has received the Presidential Award for Excellence from the Hariri Foundation in 1997. Dr. Jabbour&#8217;s research experience encompasses flexible-roll-to-roll-electronics and displays, smart textile, moisture and oxygen barrier technology, transparent conductors, organic light emitting devices, organic and hybrid photovoltaics, organic memory storage, organic thin film transistors, combinatorial discovery of materials, nano and macro printed devices, micro and nanofabrication, biosensors, and quantum simulations of electronic materials. Dr. Jabbour attended Northern Arizona University, the Massachusetts Institute of Technology (MIT), and the University of Arizona and is an SPIE fellow. Prof. Jabbour has authored and co-authored over 300 publications, invited talks, and conference proceedings. He is the editor of several books and symposia proceedings involving organic photonics and electronics, and nanotechnology. Prof. Jabbour is the guest editor of the MRS Bulletin issue on &#8220;Organic Photovoltaics&#8221;. He is the Chair and/or Co-Chair of over 50 conferences related to photonic and electronic properties of organic materials and their applications in displays and lighting, hybrid photosensitive materials, and hybrid integration of semiconducting and nanotechnology.</p>
<h3>Board of Directors</h3>
<h4>Dr. Michael S. Wong &#8211; Principal Investigator, Associate Professor in Chemical and Biomolecular Engineering , Associate Professor in Chemistry (Joint Appointment)</h4>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/pick6.jpg"><img class="alignleft size-full wp-image-41" title="pick6" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/pick6.jpg" alt="" width="200" height="142" /></a>Dr. Michael S. Wong joined the Department of Chemical Engineering in 2001, and received a joint appointment in the Department of Chemistry in 2002. Before coming to Rice University, he did post-doctoral research with Dr. Galen D. Stucky of the Department of Chemistry and Biochemistry at University of California, Santa Barbara. Michael&#8217;s educational background includes a B.S. in Chemical Engineering from Caltech, an M.S. in Chemical Engineering Practice (&#8220;Practice School&#8221;) from MIT, and a Ph.D. in Chemical Engineering from MIT (under the supervision of Dr. Jackie Y. Ying, &#8220;Supramolecular Templating of Mesoporous Zirconia-Based Nanocomposite Catalysts&#8221;). With the underlying theme of designing and engineering novel materials for catalytic and encapsulation applications, his research interests lie in the areas of nanostructured materials (e.g. nanoporous materials, nanoparticle-based hollow spheres, and quantum dots), heterogeneous catalysis, and bioengineering applications. He is particularly interested in developing new chemical app roaches to assembling nanoparticles into functional macrostructures.</p>
<h5>Awards and Achievements</h5>
<p>Smithsonian Magazine &#8220;37 Under 36&#8243; Young Innovator Award (2007)<br />
3M Non-tenured Faculty Award (2006, 2007)<br />
GOLD 2006 Conference Best Presentation Award, for &#8220;best new idea in gold catalysis&#8221; (2006)<br />
AIChE South Texas Section Best Applied Paper Award (2006)<br />
AIChE Nanoscale Science and Engineering Forum Young Investigator Award (2006)<br />
MIT Technology Review&#8217;s TR35 Young Innovator Award (2006)<br />
Hershel M. Rich Invention Award (2006)<br />
National Academy of Engineering Indo-America Frontiers of Engineering Symposium, Invited Speaker (2006)<br />
Smalley/Curl Innovation Award (2005)<br />
National Academies Keck Futures Initiative (NAKFI) Symposium, Invited Participant (2004)<br />
Oak Ridge Associated Universities Ralph E. Powe Junior Faculty Enhancement Award (2003)<br />
National Academy of Engineering Japan-America Frontiers of Engineering (JAFOE)<br />
Symposium, Invited Participant (2002)<br />
Rice Quantum Institute (RQI), Fellow (2002)<br />
Robert P. Goldberg Grand Prize, MIT $50K Entrepreneurship Competition (2001)<br />
Union Carbide Innovation Recognition Award (2000)<br />
MIT Chemical Engineering Edward W. Merrill Outstanding Teaching Assistant Award (1997)<br />
Faculty advisor for Phi Lambda Upsilon, chemical sciences honorary society (2003 &#8211; present)</p>
<h4>Ghassan E. Jabbour &#8211; PhD and Director of Flexible and Organic Electronics Development at the Flexible Display Center (FDC) and a Professor of Chemical and Materials Engineering at Arizona State University</h4>
<p>Professor Jabbour is also the Technical Advisory Board Leader on Optoelectronic Materials, Devices and Encapsulation at FDC. He has been selected to the Asahi Shimbun 100 New Leaders of the USA and has received the Presidential Award for Excellence from the Hariri Foundation in 1997. Dr. Jabbour&#8217;s research experience encompasses flexible-roll-to-roll-electronics and displays, smart textile, moisture and oxygen barrier technology, transparent conductors, organic light emitting devices, organic and hybrid photovoltaics, organic memory storage, organic thin film transistors, combinatorial discovery of materials, nano and macro printed devices, micro and nanofabrication, biosensors, and quantum simulations of electronic materials. Dr. Jabbour attended Northern Arizona University, the Massachusetts Institute of Technology (MIT), and the University of Arizona and is an SPIE fellow. Prof. Jabbour has authored and co-authored over 300 publications, invited talks, and conference proceedings. He is the editor of several books and symposia proceedings involving organic photonics and electronics, and nanotechnology. Prof. Jabbour is the guest editor of the MRS Bulletin issue on &#8220;Organic Photovoltaics&#8221;. He is the Chair and/or Co-Chair of over 50 conferences related to photonic and electronic properties of organic materials and their applications in displays and lighting, hybrid photosensitive materials, and hybrid integration of semiconducting and nanotechnology.</p>
<h4>Kim Pichanick &#8211; Principal KPN Advisors, LLC</h4>
<p>Ms. Pichanick currently provides strategic global communications and investor relations&#8217; counsel to align with overall business and financial objectives. In January 2008, Kim was appointed Outside Director, ThinOps Communications, LLC, headquartered in Houston, Texas. She is also a principal at KPN Holdings, LLC, KPN Holdings, LLC, an affiliated Company to KPN Advisors, LLC. KPN Holdings is a significant shareholder of QED Clinical, LLC, d/b/a CINA, a provider of elegant healthcare software data communications solutions. Kim is Principal and majority owner of The Hardersen Group, LLC, (&#8220;THG&#8221;) with offices in Jupiter, Florida and Dallas, Texas. THG provides strategies to protect and preserve wealth for financially mature clients. Prior to KPN Advisors, Kim was Director of Communications and Investor relations at Aleris International, Inc. where she supported Aleris&#8217;s senior management team to develop a communications function and global communications strategy that significantly contributed to Aleris&#8217;s growth from 2,100 employees to 9,100 employees and an increase in annual revenue from approximately $2 billion to approximately $9 billion from December 2004 through December 2007.</p>
<h3><span style="font-family: Geneva,Arial,Helvetica,sans-serif; font-size: x-small;"><span style="font-family: Arial,Helvetica,sans-serif; font-size: x-small;"> </span></span></h3>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/02/hague-corp-hgue-solterra-renewable-technologies-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Xtreme Oil &amp; Gas, Inc.</title>
		<link>http://www.shareholdervision.com/2010/02/client-1/</link>
		<comments>http://www.shareholdervision.com/2010/02/client-1/#comments</comments>
		<pubDate>Wed, 10 Feb 2010 05:47:55 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Video]]></category>

		<guid isPermaLink="false">http://www.shareholdervision.com/wp/?p=6</guid>
		<description><![CDATA[Xtreme Oil &#038; Gas, Inc. headquartered in Dallas, Texas, is an independent oil and gas exploration and production company.]]></description>
			<content:encoded><![CDATA[<p><img src='http://www.shareholdervision.com/wp-content/plugins/simple-post-thumbnails/timthumb.php?src=/wp-content/thumbnails/6.png&amp;w=200&amp;h=150&amp;zc=1&amp;ft=jpg' alt='post thumbnail' /></p>
<h2>Xtreme Oil &amp; Gas, Inc.</h2>
<p><strong>OTC: XTOG</strong></p>
<p>5700 W. Plano  Parkway, Suite 3600<br />
Plano, Texas 75093</p>
<p>Phone: 214-432-8002</p>
<p>Website:</p>
<p><a href="http://www.xtremeoilandgas.com/">www.xtremeoilandgas.com</a></p>
<p>Email:</p>
<p><a href="mailto:will@xtremeoilgas.com">will@xtremeoilgas.com</a></p>
<h2>About the Featured Company</h2>
<p><a href="http://www.shareholdervision.com/wp-content/uploads/2010/02/xtog-image-thing.jpg"><img class="aligncenter size-full wp-image-127" title="xtog-image-thing" src="http://www.shareholdervision.com/wp-content/uploads/2010/02/xtog-image-thing.jpg" alt="" width="600" height="449" /></a></p>
<p><span><em>Doing what it takes to bring in a new  well!</em></span></p>
<p><span>Xtreme Oil &amp; Gas, Inc.  headquartered in Dallas, Texas, is an independent oil and  gas exploration and production company which  either obtains producing wells with the  expectation of rehabbing the wells in an effort  to increase production or drill new wells in  the hope of obtaining oil and gas  production in commercial quantities. Xtreme  has purchased controlling interest in Small  Cap Strategies, Inc. BB.SMC</span></p>
]]></content:encoded>
			<wfw:commentRss>http://www.shareholdervision.com/2010/02/client-1/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

